<!DOCTYPE html>
<html>
<head>
<title>EXEL Exelixis, Inc. Stock Quote</title>
<meta charset="UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=edge">
                         <meta name="viewport" content="width=1024"><meta name="description" content="Stock screener for investors and traders, financial visualizations.">
<meta name="keywords" content="Stock Screener, Charts, Quotes, Maps, News, Financial Visualizations, Research, Trading Systems">
<meta http-equiv="imagetoolbar" content="no">
<meta http-equiv="pragma" content="no-cache">
<meta http-equiv="cache-control" content="no-cache">
<meta http-equiv="Expires" content="-1">

            <link rel="preload" href="/fonts/lato-v17-latin-ext_latin-regular.woff2" as="font" crossorigin>
            <link rel="preload" href="/fonts/lato-v17-latin-ext_latin-700.woff2" as="font" crossorigin>
            <link rel="preload" href="/fonts/lato-v17-latin-ext_latin-900.woff2" as="font" crossorigin>
            <link rel="preload" href="/fonts/inter-latin.woff2" as="font" crossorigin>
        <link rel="stylesheet" href="/assets/dist/finviz.eb62a283.css" type="text/css">
<link rel="stylesheet" href="/assets/dist/main.80b04378.css" type="text/css">
<link rel="icon" type="image/png" href="/favicon_2x.png" sizes="32x32">
<link rel="icon" type="image/png" href="/favicon.png" sizes="16x16">
<script type="text/javascript">FinvizSettings = {hasUserPremium: false, name: "", chartsDomain: "https://charts2.finviz.com"};</script><script src="/script/boxover.js?rev=282" type="text/javascript"></script>
<script type="text/javascript" src="/js/libs/shims.min.js?rev=282"></script><script type="text/javascript" src="/js/libs/d3-json.js"></script><script src="/script/libs/bowser2.min.js?rev=282" type="text/javascript"></script>
            <script type="text/javascript" src="/assets/dist/runtime.180823fc.js"></script>
            <script type="text/javascript" src="/assets/dist/vendors.082a8b09.js"></script>
            <script type="text/javascript" src="/assets/dist/libs_init.5bbec9f1.js"></script>
            <script type="text/javascript" src="/assets/dist/header.3eb461e7.js"></script>
        <script src="/script/ajax.js" type="text/javascript"></script>
<script src="/script/ta_settings.js?rev=282" type="text/javascript"></script>
<script>FinvizSettings.hasNewQuoteMenu = false;</script>
            <script src="/js/dfp.min.js"></script>
            <script>
                if(window['FinvizLoadIC']) {
                    var s = document.createElement('script');
                    s.type = 'text/javascript';
                    s.async = true;
                    s.src = 'https://u5.investingchannel.com/static/uat.js';
                    document.head.appendChild(s);

                    InvestingChannelQueue = window.InvestingChannelQueue || [];
                    var ic_page;
                    InvestingChannelQueue.push(function() {
                        ic_page = InvestingChannel.UAT.Run('df0d0d52-cc7f-11e8-82a5-0abbb61c4a6a');
                    });
                } else {
                    (function() {
                        function ready(fn) {if (document.readyState != 'loading'){fn();}else{document.addEventListener('DOMContentLoaded', fn);} }
                        ready(function() {
                            var banners = ['2', '4', '5', '6', '7'];
                            var banner = banners[Math.floor(Math.random() * banners.length)];

                            if (banner === '3') {
                                document.getElementById('banner_position').innerHTML = '<iframe src="/img/a/' + banner + '/index.html?rev=2" frameBorder="0" width="728" height="90"></iframe>';
                            } else {
                                document.getElementById('banner_position').innerHTML = '<a href="/elite.ashx?utm_source=finviz&utm_medium=banner&utm_campaign=' + banner + '"><img src="/img/a/' + banner + '.jpg"></a>';
                            }
                            gtag && gtag('event', 'impression', { event_category: 'banner', event_label: banner, non_interaction: true });
                        })
                    })();
                }
            </script></head>
<body class="yellow-tooltip" style="margin:0" bgcolor="#ffffff"><div id="unsupported-browser">Your browser is no longer supported. Please, <a href="https://browser-update.org/update.html" target="_blank">upgrade your browser.</a></div>
                <table class="header" width="100%" cellpadding="0" cellspacing="0" border="0" style="min-width: 1000px">
                    <tr valign="top">
                        <td>
                            <script type="text/javascript">if(document.body.clientWidth>1500){document.write('<table align="center" width="1425px" cellpadding="0" cellspacing="0" border="0" style="table-layout: fixed; min-width: 1000px">')}else{document.write('<table align="center" width="95%" style="max-width: 1425px; min-width: 1000px; table-layout: fixed" cellpadding="0" cellspacing="0" border="0">')}</script>
                                <tr>
                                    <td width="30%">
                                        <table width="100%" cellpadding="0" cellspacing="0" border="0">
                                            <tr>
                                                <td height="50" valign="middle">
                                                    <a href="/" class="logo"></a>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td class="search" id="search" style="padding-top: 4px">
                                                    <form style="margin: 0">
                                                        <input placeholder="Search ticker, company or profile" type="text" value="">
                                                        <span class="fa fa-search"></span>
                                                    </form>
                                                </td>
                                            </tr>
                                        </table>
                                    </td>
                                    <td valign="bottom" style="padding-bottom: 4px">
                                        <div id="microbar_position" style="height: 31px"></div>
                                    </td>
                                    <td width="728" align="right" style="position:relative;"><div id="banner_position" style="position:absolute;right:0;top:0;overflow:hidden;height:96px"></div></td>
                                </tr>
                            </table>
                        </td>
                    </tr>
                    <tr>
                        <td width="1000" style="font-size:0">
                            <img src="/gfx/nic2x2.gif" width="1000" style="height:1px" border="0">
                        </td>
                    </tr>
                </table>
            <table class="navbar" width="100%" height="30" cellpadding="0" cellspacing="0" border="0">
                <tr>
                    <td height="30">
                        <script type="text/javascript">if(document.body.clientWidth>1500){document.write('<table align="center" width="1425px" cellpadding="0" cellspacing="0" border="0" style="white-space: nowrap; min-width: 1000px">')}else{document.write('<table align="center" width="95%" style="max-width:1425px;white-space: nowrap;min-width: 1000px" cellpadding="0" cellspacing="0" border="0">')}</script>
                            <tr height="30"><td><a class="nav-link  is-first" href="/">Home</a></td><td><a class="nav-link " href="/news.ashx">News</a></td><td><a class="nav-link " href="/screener.ashx">Screener</a></td><td><a class="nav-link " href="/map.ashx">Maps</a></td><td><a class="nav-link " href="/groups.ashx">Groups</a></td><td><a class="nav-link " href="/portfolio.ashx">Portfolio</a></td><td><a class="nav-link " href="/insidertrading.ashx">Insider</a></td><td><a class="nav-link " href="/futures.ashx">Futures</a></td><td><a class="nav-link " href="/forex.ashx">Forex</a></td><td><a class="nav-link " href="/crypto.ashx">Crypto</a></td><td><a class="nav-link " href="/backtests.ashx">Backtests</a></td><td><a class="nav-link  is-elite" href="/elite.ashx">Elite</a></td><td style="width: 100%"></td>
                                <td class="time" id="time"></td>
                <td>
                    <a href="/help/screener.ashx" class="nav-link is-help">
                        <span class="fa fa-question-circle"></span>
                        Help
                    </a>
                </td>
                <td><a href="/login.ashx" class="nav-link sign-in">Login</a></td>
                <td><a href="/register.ashx" class="nav-link sign-up">Register</a></td>
            
                            </tr>
                        </table>
                    </td>
                </tr>
            </table>
        <div class="content "><div class="fv-container">
                    <div id="quote-ad" style="background: #fffce5; border: 1px solid #fee500; color: #363a46; display: none; font-family: Lato; font-size: 13px; line-height: 36px; text-align: center; width: 945px; margin: 10px auto 10px auto;position: relative;">
                        <b>TIP: </b>
                        <a href="/elite.ashx?utm_source=finviz&utm_medium=banner&utm_campaign=quote" target="blank" onclick="gtag('event', 'click', { event_category: 'bannerQuote' });" style="color: #1E6DC0;">Upgrade to FINVIZ*Elite</a> to get real-time quotes, intraday charts, and advanced charting tools.
                        <a title="Close" class="close" onclick="Finviz.quoteAd.close();" href="javascript:void(0)" style="
                            position: absolute;
                            margin-right: 0;
                            right: 10px;
                            color: #363a46;
                            text-decoration: none;
	                    ">Ã—</a>
                    </div>
                    <script src="/js/quote_a.js?rev=2" async></script>
        <table  style="margin: 21px auto 14px auto" cellpadding="0" cellspacing="0" border="0">
<tr>
<td class="fullview-links" align="left" valign="center">
<a href="javascript:void(0)" class="tab-link" id="publish-chart">publish chart</a> | <a href="/save_to_portfolio.ashx?t=EXEL" class="tab-link">save to portfolio</a> | <a href="/create_alert.ashx?t=EXEL" class="tab-link">create alert</a>&nbsp;<img src="/gfx/nic2x2.gif" style="width:20px;height:14px" border="0" alt=""><span class="count-text"><b>Type:</b></span> <a href="quote.ashx?t=EXEL&ty=c&ta=0&p=d" class="tab-link" data-testid="quote-compare-perf-link">candle</a> | <a href="quote.ashx?t=EXEL&ty=l&ta=0&p=d" class="tab-link" data-testid="quote-compare-perf-link">line</a> | <a href="quote.ashx?t=EXEL&ty=c&ta=1&p=d" class="tab-link" data-testid="quote-compare-perf-link"><b>advanced</b></a> | <a href="/elite.ashx" class="tab-link">interactive</a> | <a href="/elite.ashx" class="tab-link">perf</a>&nbsp;&nbsp;&nbsp;&nbsp;<span class="count-text"><b>Timeframe:</b></span> <a href="elite.ashx" class="tab-link">intraday</a> | </span><a href="quote.ashx?t=EXEL&ty=c&ta=1&p=d" class="tab-link"><b>daily</b></a> | <a href="quote.ashx?t=EXEL&ty=c&ta=0&p=w" class="tab-link">weekly</a> | <a href="quote.ashx?t=EXEL&ty=c&ta=0&p=m" class="tab-link">monthly</a>&nbsp;&nbsp;</td><td align="left" valign="top" class="ta-settings-button" style="position: relative"><a href="elite.ashx" class="ta-settings-button">Settings<img src="gfx/ta_settings_arrow_d.gif" width="21" height="9" alt="" border="0"></a></td>
</tr>
</table>
<div id="js-settings-portal"></div></div></div><script>
            FinvizSettings.TA = {"style":"candlestick","overlays":[{"name":"sma","parameters":"20","color":"rgba(220,  50, 179, 0.39)"},{"name":"sma","parameters":"50","color":"rgba(255, 143,  51, 0.78)"},{"name":"sma","parameters":"200","color":"rgba(220, 179,  50, 0.43)"},{"name":"patterns","parameters":"","color":"rgba(135, 206, 239, 1)|rgba(220, 159, 229, 1)"}],"indicators":[]};
        </script><div style="display: flex; flex-direction: column; align-items: center">
                <script>
                    function setDarkerBorderWickColors() {
                        
            var Settings = FLibs.Charts.Settings.default;
            Settings.updateColors('chart', 'borderUp', 'light', '#006400');
            Settings.updateColors('chart', 'wickUp', 'light', '#006400');
            Settings.updateColors('chart', 'borderDown', 'light', '#6e0000');
            Settings.updateColors('chart', 'wickDown', 'light', '#6e0000');
        
                    };
                    function checkSmallDisplay(configObject) {
                        if ('d' === 'd' && window['FinvizSmallDisplay'] === true) {
                            configObject.barWidth = 2;
                            configObject.barMargin = 0;
                            setDarkerBorderWickColors();
                            window['FinvizChartWidth'] = 990;
                        }

                        configObject.width = FinvizChartWidth;
                    }
                </script>
            
            <script type="text/javascript" src="/js/jscolor/jscolor.js"></script>
            <link rel="stylesheet" href="/assets/dist-charts/main.3de72d0e.css">
            <div id="app" class="interactive-chart">
                <div id="chart" style="min-height: 400px; position: relative"></div>
            </div>
            <div id="js-charts-modal"><div class="overlay modal hidden has-footer"></div></div>
            <div class="context-menu hidden"></div>
            
            <script>
                (function(){
                    var app = document.getElementById('app');
                    var chart = document.getElementById('chart');
                    window['FinvizChartWidth'] = 1280;
                    var browserWidth = Math.max(document.documentElement.clientWidth, window.innerWidth || 0);
                    if (browserWidth <= 1280){
                        window['FinvizChartWidth'] = 992;
                        window['FinvizSmallDisplay'] = true;
                    }

                    function checkMediaQuery(matches) {
                      if (matches) {
                        app.classList.add('small');
                      } else {
                        app.classList.remove('small');
                      }
                    }

                    var mediaMatch = window.matchMedia('(max-width: 1510px)');
                    checkMediaQuery(mediaMatch.matches);
                    mediaMatch.addListener(function (ev) { checkMediaQuery(ev.matches) });
                } ())
            </script>
            <script type="text/javascript" src="/assets/dist-charts/vendors.b0dc4172.js"></script>
            <script type="text/javascript" src="/assets/dist-charts/main.eb7d29bb.js"></script>
        <div style="font-family:Verdana;font-size:11px;display:none;margin-bottom:15px" id="js-idea-note">Note:<br><textarea style="width:1280px;height:60px;display:block;border:1px solid #d3d3d3;padding: 2px 5px" id="note"></textarea></div><script>
                                    (function() {
                                        var Quote = FLibs.Charts.Quote;
                                        var data = {"ticker":"EXEL","timeframe":"d","volume":[2304019,2166911,2363475,7835303,5236813,4081028,3232090,5525430,5674802,3066131,2753458,5869764,2360020,3240122,3085616,2509842,3489366,3036368,3143703,2129567,2297442,2447839,2622863,2285211,4817471,3368149,3842839,3680637,2870396,2321501,3489295,3764141,3570358,5463972,4975167,3665328,3525951,5110723,4710664,3628377,5178382,14052794,6335073,4524583,4173240,3501081,4282321,4449021,4057430,4763953,4811015,4527879,5357597,4070098,2555570,1365673,4104017,2651586,5043457,4304845,3573954,5604134,5402944,4602259,3637508,3868517,3126080,4612208,3286466,3436409,3783511,4460737,6212518,7026773,9182180,2073915,2643058,3418785,3242129,2690807,2897317,4692628,6101836,4551559,6114925,4372404,3628556,4010066,4046759,6390692,4154952,4333354,5942769,3650370,5206331,3439295,4239815,3807440,2686652,3089832,4536942,3945896,2838135,3844927,3433307,6138399,4571065,3282433,6210927,10182604,5323668,4092050,4847267,3957368,2082281,1846966,3887774,2704538,2815972,3045615,3031352,3172340,3655546,2973820,2727204,2124990,2762748,2957195,5214715,3983198,4141835,5424562,2731534,2421797,2339960,3677078,2422743,1586634,1758642,2058628,2806969,2570375,2081970,5911636,2528868,3042538,1952332,2364235,2010567,2181917,2259544,1577898,1573443,3749983,4162462,3428792,4796729,5292156,7836860,3340769,4728230,3310820,4749070,6100405,4054683,3585691,3262638,2241790,3589226,4187613,3647549,3020066,1991559,2034123,2901165,2941767,2799053,3250493,3080199,2113407,1892745,3377853,2013068,2965451,2888231,3286124,2133335,1966561,1421562,2165059,1807392,1517637,2712167,1970428,4210553,2593198,1526404,3168251,5606100,2785364,2123966,1869266,1722338,7163178,2110779,1855727,1087999,1173499,2740924,1846217,1464993,1937205,1565456,2103633,2054734,1792102,2035861,2385542,1681125,2744307,2535898,1982853,1491037,1738781,2097051,3602298,4864375,2561845,3841353,2337155,1648689,2728495,1680733,2600222,2338320,2376902,2726074,7428965,3721461,2862835,3562542,2474287,2580570,3230439,2653339,1892444,2198927,4568970,4025659,3529391,2031990,1497606,2134464,1850301,1742393,1664084,2750537,1237773,1694216,1501381,2512011,5068007,1624857,3219907,3308982,2010104,3368783,2020178,2436573,1819160,1801313,3671437,2326650,3603946,2268443,2488815,2800727,1267065,2815551,2178045,2111938,2583625,2142492,1992478,1622160,2012910,1805698,1716792,2791454,3251437,9199621,5322774,4601986,3148260,2964262,2812160,2684890,3379444,2269806,3837986,4919714,2148866,2223334,1820206,2804254,2487602,2272720,2092708,2033164,1967004,1018535,2966551,3974701,4103156,3657866,3214737,2884220,3468639,3465217,2580558,3079206,2873638,3070278,2714673,2904600,7558384,2459250,1139269,1844369,2211760,2156612,1748201,2952217,2330951,3189945,5433255,3276580,2999454,3148510,4668219,4666842,8019742,4441030,2525554,3180001,2868870,3315462,4722818,3561355,2326604,1886677,2251793,2327502,3134579,2332211,3092218,2692059,4113584,2803839,4656398,5107000,5439697,3990732,3232980,4232026,3384807,2297769,3974868,4348909,4351166,4198829,5422092,3753064,4544880,2991319,2895525,3287224,4179469,4180407,3287881,5338446,5017919,5037199,5004055,4784215,5898992,4164830,3347814,2560412,3607915,2872433,2080347,1882788,2695436,2850314,2510971,7044526,6165027,5596826,4235160,2958706,1565291,2429346,2844302,3360973,2916071,18410600,8345825,3569165,5343724,6437457,3394072,4339543,3215639,5338820,3735794,4100814,3336360,4615474,3268424,3378035,4175870,3404442,2729540,5734600,3460316,2807249,2624498,2736266,3139834,2112938,5193064,2617401,1976413,2852303,2387436,2592184,2480676,3411253,1889233,1982016,2013482,2581922,2333985,3011751,2144388,2791837,2368414,1922832,7474902,2642028,2530404,1626450,1275815,2530435,1340245,4946687,2172069,1383552,1622041,2984749,2073738,2158160,3661114,2389574,3965520,1741622,1403776,2176079,2654972,1770037,1409231,2515696,1811366,1660090,1245828,1996538,1836986,1977624,1405428,1594998,2470918,2145137,2725887,2062828,2412127,1889980,1366626,1384166,2090372,1517315,1855477,1116276,937116,1652361,989325,1797032,1981899,1044585,1395079,1360064,1048454,1462714,1442146,1932778,1165766,1265593,2267936,4516205,2526865,5462737,3324752,4138630,4399829,1918173,2919185,2473014,2144220,1137847,2066462,1658934,1216980,1780791,1524839,1270076,1100579,1371315,2454682,1747218,2038678,1531142,1296698,1419760,2171796,1789081,1774715,4294714,1828886,1620570,1160120,1301496,1661066,1988635,1208482,1466816,2055678,2181255,3179254,2021632,2028253,1348652,1525312,1929104,2151987,2316398,3534476,2262321,2987883,3094988,1751844,1988616,1740245,3247690,1873609,1793575,2485414,1332279,1522877,1500940,1665257,2243562,2352188,3337806,2678970,1821639,3371512,6263010,2467417,1531897,1543588,1136714,2866799,1506582,1641473,1649451,2346102,3158203,4591218,2293805,3861960,3437441,3493093,2472988,3229716,2171307,1795275,6136578,2779936,3736127,2537385,1707981,2309062,2034515,1784852,1785971,1682508,1655018,1745098,2544640,1695926,2107658,1375825,4258011,3557146,3567614,2896174,2024176,1223319,1447161,1661237,1444153,1379317,1764646,1504529,2010292,1113732,1579563,2005662,2546707,2247045,1599344,1438508,1508109,2127044,1827990,1441189,1299322,4245365,1604442,1788953,1971802,1880321,1247494,1719072,1395509,2116908,1613497,1747979,2272512,1522632,1086895,1491725,2054252,959469,1544582,1161575,1721000,1305059,1787493,1561203,870032,1528987,1338542,1551579,865613,658615,1408101,1377114,1507977,2201649,1910883,2409450,2180445,2246029,1977722,1652933,1335423,850130,1495582,1980212,1552254,1518273,987513,2947650,1970602,1162266,1875395,1386640,2251469,1181169,871707,1996465,1703802,1363677,1308608,758109,1188624,1170120,1046650,1285096,1133152],"date":[1536238800,1536325200,1536584400,1536670800,1536757200,1536843600,1536930000,1537189200,1537275600,1537362000,1537448400,1537534800,1537794000,1537880400,1537966800,1538053200,1538139600,1538398800,1538485200,1538571600,1538658000,1538744400,1539003600,1539090000,1539176400,1539262800,1539349200,1539608400,1539694800,1539781200,1539867600,1539954000,1540213200,1540299600,1540386000,1540472400,1540558800,1540818000,1540904400,1540990800,1541077200,1541163600,1541426400,1541512800,1541599200,1541685600,1541772000,1542031200,1542117600,1542204000,1542290400,1542376800,1542636000,1542722400,1542808800,1542981600,1543240800,1543327200,1543413600,1543500000,1543586400,1543845600,1543932000,1544104800,1544191200,1544450400,1544536800,1544623200,1544709600,1544796000,1545055200,1545141600,1545228000,1545314400,1545400800,1545660000,1545832800,1545919200,1546005600,1546264800,1546437600,1546524000,1546610400,1546869600,1546956000,1547042400,1547128800,1547215200,1547474400,1547560800,1547647200,1547733600,1547820000,1548165600,1548252000,1548338400,1548424800,1548684000,1548770400,1548856800,1548943200,1549029600,1549288800,1549375200,1549461600,1549548000,1549634400,1549893600,1549980000,1550066400,1550152800,1550239200,1550584800,1550671200,1550757600,1550844000,1551103200,1551189600,1551276000,1551362400,1551448800,1551708000,1551794400,1551880800,1551967200,1552053600,1552309200,1552395600,1552482000,1552568400,1552654800,1552914000,1553000400,1553086800,1553173200,1553259600,1553518800,1553605200,1553691600,1553778000,1553864400,1554123600,1554210000,1554296400,1554382800,1554469200,1554728400,1554814800,1554901200,1554987600,1555074000,1555333200,1555419600,1555506000,1555592400,1555938000,1556024400,1556110800,1556197200,1556283600,1556542800,1556629200,1556715600,1556802000,1556888400,1557147600,1557234000,1557320400,1557406800,1557493200,1557752400,1557838800,1557925200,1558011600,1558098000,1558357200,1558443600,1558530000,1558616400,1558702800,1559048400,1559134800,1559221200,1559307600,1559566800,1559653200,1559739600,1559826000,1559912400,1560171600,1560258000,1560344400,1560430800,1560517200,1560776400,1560862800,1560949200,1561035600,1561122000,1561381200,1561467600,1561554000,1561640400,1561726800,1561986000,1562072400,1562158800,1562331600,1562590800,1562677200,1562763600,1562850000,1562936400,1563195600,1563282000,1563368400,1563454800,1563541200,1563800400,1563886800,1563973200,1564059600,1564146000,1564405200,1564491600,1564578000,1564664400,1564750800,1565010000,1565096400,1565182800,1565269200,1565355600,1565614800,1565701200,1565787600,1565874000,1565960400,1566219600,1566306000,1566392400,1566478800,1566565200,1566824400,1566910800,1566997200,1567083600,1567170000,1567515600,1567602000,1567688400,1567774800,1568034000,1568120400,1568206800,1568293200,1568379600,1568638800,1568725200,1568811600,1568898000,1568984400,1569243600,1569330000,1569416400,1569502800,1569589200,1569848400,1569934800,1570021200,1570107600,1570194000,1570453200,1570539600,1570626000,1570712400,1570798800,1571058000,1571144400,1571230800,1571317200,1571403600,1571662800,1571749200,1571835600,1571922000,1572008400,1572267600,1572354000,1572440400,1572526800,1572613200,1572876000,1572962400,1573048800,1573135200,1573221600,1573480800,1573567200,1573653600,1573740000,1573826400,1574085600,1574172000,1574258400,1574344800,1574431200,1574690400,1574776800,1574863200,1575036000,1575295200,1575381600,1575468000,1575554400,1575640800,1575900000,1575986400,1576072800,1576159200,1576245600,1576504800,1576591200,1576677600,1576764000,1576850400,1577109600,1577196000,1577368800,1577455200,1577714400,1577800800,1577973600,1578060000,1578319200,1578405600,1578492000,1578578400,1578664800,1578924000,1579010400,1579096800,1579183200,1579269600,1579615200,1579701600,1579788000,1579874400,1580133600,1580220000,1580306400,1580392800,1580479200,1580738400,1580824800,1580911200,1580997600,1581084000,1581343200,1581429600,1581516000,1581602400,1581688800,1582034400,1582120800,1582207200,1582293600,1582552800,1582639200,1582725600,1582812000,1582898400,1583157600,1583244000,1583330400,1583416800,1583503200,1583758800,1583845200,1583931600,1584018000,1584104400,1584363600,1584450000,1584536400,1584622800,1584709200,1584968400,1585054800,1585141200,1585227600,1585314000,1585573200,1585659600,1585746000,1585832400,1585918800,1586178000,1586264400,1586350800,1586437200,1586782800,1586869200,1586955600,1587042000,1587128400,1587387600,1587474000,1587560400,1587646800,1587733200,1587992400,1588078800,1588165200,1588251600,1588338000,1588597200,1588683600,1588770000,1588856400,1588942800,1589202000,1589288400,1589374800,1589461200,1589547600,1589806800,1589893200,1589979600,1590066000,1590152400,1590498000,1590584400,1590670800,1590757200,1591016400,1591102800,1591189200,1591275600,1591362000,1591621200,1591707600,1591794000,1591880400,1591966800,1592226000,1592312400,1592398800,1592485200,1592571600,1592830800,1592917200,1593003600,1593090000,1593176400,1593435600,1593522000,1593608400,1593694800,1594040400,1594126800,1594213200,1594299600,1594386000,1594645200,1594731600,1594818000,1594904400,1594990800,1595250000,1595336400,1595422800,1595509200,1595595600,1595854800,1595941200,1596027600,1596114000,1596200400,1596459600,1596546000,1596632400,1596718800,1596805200,1597064400,1597150800,1597237200,1597323600,1597410000,1597669200,1597755600,1597842000,1597928400,1598014800,1598274000,1598360400,1598446800,1598533200,1598619600,1598878800,1598965200,1599051600,1599138000,1599224400,1599570000,1599656400,1599742800,1599829200,1600088400,1600174800,1600261200,1600347600,1600434000,1600693200,1600779600,1600866000,1600952400,1601038800,1601298000,1601384400,1601470800,1601557200,1601643600,1601902800,1601989200,1602075600,1602162000,1602248400,1602507600,1602594000,1602680400,1602766800,1602853200,1603112400,1603198800,1603285200,1603371600,1603458000,1603717200,1603803600,1603890000,1603976400,1604062800,1604325600,1604412000,1604498400,1604584800,1604671200,1604930400,1605016800,1605103200,1605189600,1605276000,1605535200,1605621600,1605708000,1605794400,1605880800,1606140000,1606226400,1606312800,1606485600,1606744800,1606831200,1606917600,1607004000,1607090400,1607349600,1607436000,1607522400,1607608800,1607695200,1607954400,1608040800,1608127200,1608213600,1608300000,1608559200,1608645600,1608732000,1608818400,1609164000,1609250400,1609336800,1609423200,1609768800,1609855200,1609941600,1610028000,1610114400,1610373600,1610460000,1610546400,1610632800,1610719200,1611064800,1611151200,1611237600,1611324000,1611583200,1611669600,1611756000,1611842400,1611928800,1612188000,1612274400,1612360800,1612447200,1612533600,1612792800,1612879200,1612965600,1613052000,1613138400,1613484000,1613570400,1613656800,1613743200,1614002400,1614088800,1614175200,1614261600,1614348000,1614607200,1614693600,1614780000,1614866400,1614952800,1615212000,1615298400,1615384800,1615471200,1615557600,1615813200,1615899600,1615986000,1616072400,1616158800,1616418000,1616504400,1616590800,1616677200,1616763600,1617022800,1617109200,1617195600,1617282000,1617627600,1617714000,1617800400,1617886800,1617973200,1618232400,1618318800,1618405200,1618491600,1618578000,1618837200,1618923600,1619010000,1619096400,1619182800,1619442000,1619528400,1619614800,1619701200,1619787600,1620046800,1620133200,1620219600,1620306000,1620392400,1620651600,1620738000,1620824400,1620910800,1620997200,1621256400,1621342800,1621429200,1621515600,1621602000,1621861200,1621947600,1622034000,1622120400,1622206800,1622552400,1622638800,1622725200,1622811600,1623070800,1623157200,1623243600,1623330000,1623416400,1623675600,1623762000,1623848400,1623934800,1624021200],"open":[19.09,18.56,18.16,18.68,17.36,17.14,16.67,16.92,16.13,16.8,16.45,16.92,16.79,16.98,17.23,17.19,17.65,17.72,17.93,18,18.12,17.92,17.57,17.33,17.38,16.22,16.34,16.17,16.24,16.69,16.9,16.62,16.44,15.06,14.85,14.06,14.4,14.63,13.65,14.27,13.89,17.81,17.5,17.75,17.1,17.2,16.99,16.57,16.04,16.93,17.06,17.29,17.75,17.3,17.79,18.06,18.34,18.65,18.99,19.64,19.66,20.98,21.47,20.16,20.95,20.58,21.63,21.36,21.84,20.9,20.89,21.12,20.1,19.11,18.56,17.44,17.73,18.6,19.31,19.86,19.28,19.93,19.96,21.03,22.4,23.38,23.54,23.94,23.53,23.22,24.06,22.9,22.9,22.46,22.13,22.19,22.88,23.05,23.18,23.33,23.29,23.56,23.64,23.26,22.73,22.44,21.01,21.3,21.13,23.15,22,22.34,22.1,21.36,21.21,21.22,21.7,22.32,22.44,22.78,22.88,23.05,22.57,22.9,22.8,22.76,23.13,23.6,23.7,24.78,24.81,24.7,24.33,24.28,24.14,24.2,23.2,23.39,23.58,23.3,23.9,23.99,24.35,24.89,24.8,24.12,24.48,24.23,24.04,24.07,23.8,23.24,23.16,23.05,21.32,20.89,20.62,21.46,20.59,19.93,20.61,20.07,19.78,19.54,20.12,20.28,20.45,20.21,20.08,19.58,19.25,19.01,19.01,19.37,19.61,19.24,19.72,20.14,20.3,19.83,20.45,19.8,19.86,19.76,19.6,19.89,20.53,19.9,20.33,20.23,20.05,20.02,20.04,19.87,20.42,20.71,20.79,21.17,21.04,21.44,20.79,21.14,20.99,21.5,21.81,21.52,21.24,21.23,21,20.38,20.96,20.98,20.84,21.07,21.52,21.47,21.74,22.14,21.44,21.53,20.75,20.72,20.71,20.8,20.9,21.25,21.67,20.23,19.47,19.87,20.02,20.61,20.83,20.39,19.77,19.92,19.9,20.01,21.76,22.65,21.97,21.56,20.55,20.29,19.69,19.1,19.49,19.52,19.84,20.2,19.5,19.52,19.33,18.84,19.21,19.46,19.23,19.14,19.36,19.24,19.33,19.64,19.64,19.29,18.45,18.93,18,18.07,17.75,17.62,17.92,17.96,16.95,16.54,16.71,16.27,16.6,16.55,16.36,16.81,16.9,17.03,16.59,16.97,16.78,16.79,16.79,17.37,17.23,16.99,17,15.57,16.08,16.16,15.69,15.28,15.26,15.76,15.6,15.53,16.34,16.7,16.5,16.39,16.4,16.54,16.41,16.34,16.78,16.7,16.52,16.68,16.55,16.8,17.61,17.3,17.39,16.93,17.72,17.64,18.26,17.87,18.07,17.91,17.97,18.4,18.54,18.88,18.7,19,18.1,17.6,17.71,17.31,16.93,17.66,18.55,19.17,18.7,17.89,18.56,19.73,20.54,20.57,19.9,19.9,19.68,19.75,17.65,17.88,17.94,17.71,17.07,17.17,17.7,17.7,18.6,18.52,19.1,19.73,19.5,20,20.2,20.61,21.33,21.76,21.5,20.34,20.16,18.53,18.26,17.8,18.55,19.2,19.2,19.5,18.84,17.55,18.11,17.94,16.27,16.23,15.24,15.01,13.96,14.54,15.3,15.37,15.85,15.99,15.76,16.98,17.4,17.66,16.73,16.28,16.48,16.99,18,17.9,18.75,18,18.21,18.23,18.41,19.1,23,23.57,24.93,24.8,26.5,26.872,27.4,26.99,25.68,24.35,24.2,25.97,25.86,25.02,25.73,25.88,27.62,26.98,26.19,24.77,26.29,25.77,25.38,24.9,24.69,24.91,24.1,24.591,24.5,24.62,24.21,24.18,23.12,23.01,22.52,22.65,22.8,22.73,22.01,21.9,23.12,23.45,22.48,22.67,24.31,24.3,23.89,23.5,23.75,22.95,22.64,23.91,23.42,23.201,22.72,23.55,23.96,24.29,25.2,23.97,23.96,24.25,24.23,24.89,25.54,24.8,24.91,24.73,24.75,24.63,25.04,23.618,23.93,23.31,23.51,23.37,23.03,23.15,22.45,21.75,21.6,21.88,22,22.14,23,22.5,22.27,22.32,22.31,21.56,21.8,21.63,21.81,21.73,22.11,21.62,21.9,20.74,20.65,20.99,21.13,21.1,22.45,24.86,25.38,26.74,26.99,26.49,26.14,25.52,23.51,23.193,24.1,23.8,24.49,24.59,24.14,23.65,24.03,23.65,24.19,25.06,24,23.99,24.15,23.36,23.57,23.74,22.6,22.38,21.76,22.08,21.83,22,21.46,20.98,20.79,20.75,20.68,21.54,22.65,21,21.11,21.01,21.43,20.71,20.38,20.31,19.57,19.39,19.27,19,18.98,18.5,18.62,18.93,19.63,19.42,19.07,19.34,18.81,18.88,18.95,19.06,18.77,19.34,20.09,20.72,20.75,20.24,20.37,20.06,20.02,20.01,20.69,20.899,20.38,20.21,20.1,20.18,20.6,21.18,22.02,22.67,24.1,24.39,25.1,24.338,23.76,23.76,23.6,22.41,21.23,22.22,22.91,22.2,22.32,22.54,22.5,22.49,22.52,23.16,22.97,23.52,23.98,23.24,22.78,21.79,22.02,22.02,22.44,22.49,21.98,21.64,22.36,22.7,22,21.86,22.21,22.1,21.25,21.5,22.15,22.3,22.37,22.17,22.75,23.4,24.17,23.24,22.92,22.98,23.45,23.47,22.78,21.78,22,22.55,21.88,22.38,22.76,22.96,23.34,23.44,23.58,23.25,23.1,23.16,23.33,24.29,23.91,23.64,23.58,24.51,24.52,24.64,24.96,25.01,24.48,24.78,24.5,24.68,24.67,23.81,23.76,23.4,25.009,24.11,24.55,25.21,25.03,25.54,24.73,23.97,23.73,24.35,24.69,23.62,22.5,22.44,22.74,22.6,22.82,22.2,22.32,22.29,22.24,22.4,22.79,22.85,23.09,23.15,22.6,22.17,22.06],"high":[19.09,18.79,18.94,18.76,17.53,17.14,17.27,17.08,16.885,16.98,16.92,17,16.96,17.335,17.7,17.79,17.995,17.99,17.97,18.32,18.24,18.22,17.75,17.71,17.46,16.45,16.44,16.2,16.94,17.1,16.95,16.92,16.64,15.31,15.24,14.97,14.58,14.79,14.14,14.49,15.22,19.2,18.189,18.16,17.45,17.75,17.23,16.77,16.82,17.34,17.49,18.04,18.165,17.83,18.37,18.69,18.81,18.92,19.73,20.04,20.35,21.58,21.66,21.11,21.54,21.5,21.77,22.374,21.98,21.52,21.61,21.23,20.97,19.44,18.87,18.04,18.97,19.26,19.81,20.07,20.01,20,20.82,22.01,23.44,23.86,24.1,24.25,23.7,24.19,24.065,23.58,23.03,22.63,22.31,22.757,23.29,23.44,23.315,23.39,23.82,23.72,23.69,23.65,23.04,22.44,21.333,21.56,21.92,23.59,22.66,22.66,22.13,21.67,21.48,21.52,22.5,22.88,23,22.9,23.05,23.21,23.305,23.015,23.245,23.3,23.66,23.83,25,25.19,25.12,25.31,24.58,24.79,24.51,24.38,23.32,23.7,23.71,23.73,24.03,24.35,24.78,25.2,25,24.73,24.585,24.515,24.27,24.47,23.93,23.58,23.25,23.07,21.56,20.95,21.48,21.476,20.75,20.6,20.72,20.34,19.92,20.24,20.885,20.7,20.92,20.715,20.18,19.87,19.31,19.33,19.36,19.801,19.81,19.74,20.44,20.62,20.32,20.41,20.67,20.1,20.24,20.105,19.97,20.52,20.53,20.25,20.46,20.37,20.17,20.14,20.12,19.925,20.975,20.88,20.99,21.46,21.69,21.639,21.37,21.4,21.47,21.68,21.81,21.55,21.34,21.45,21,21.08,21.22,20.98,21.08,21.75,21.68,21.85,22.34,22.25,21.69,21.69,20.86,20.91,20.9,21.035,21.205,21.742,21.67,20.58,19.86,20.28,20.56,21.115,21.04,20.49,20.46,20.29,20.05,21.89,23,22.76,22,21.56,20.83,20.296,19.97,19.58,19.6,20.317,20.35,20.2,19.77,19.71,19.442,19.381,19.5,19.59,19.541,19.44,19.48,19.39,19.88,20.04,19.74,19.45,19.21,19,18.435,18.185,18.06,18.09,18.09,17.98,17.13,16.72,16.86,16.77,16.78,16.65,17.07,17.085,17.125,17.09,16.85,17.38,17.005,16.92,17.31,17.428,17.255,17.48,17.1,16.07,16.45,16.18,15.79,15.488,15.816,15.76,15.765,16.52,16.875,16.8,16.54,16.71,16.65,16.54,16.42,16.86,16.93,16.77,16.89,16.93,16.72,17.72,17.76,17.53,17.5,17.79,18.14,17.78,18.32,18.24,18.17,17.99,18.42,18.58,18.8,18.89,19.03,19.03,18.14,17.88,17.769,17.39,17.59,18.8,19.15,19.17,18.7,18.77,19.72,20.75,20.76,20.57,20.09,20,19.75,19.8,18.02,18.1,18.08,17.8,17.35,17.5,17.91,18.7,18.76,19.18,19.26,20.37,20.12,20.54,21.05,21.26,22.06,21.89,21.51,20.45,20.5,19.93,19.11,18.65,19.31,19.8,19.93,19.72,19.05,18.3,18.465,18.26,16.54,16.84,16.4,15.1,16.21,15.58,16.08,15.61,16.11,16.4,17.28,17.95,17.78,18.165,17.17,16.73,16.95,17.69,18.59,18.68,18.98,18.04,18.69,18.58,18.68,19.47,24.9,25.128,25.2,26.476,26.74,27.655,27.5,27.1,25.75,24.59,25.66,26,26.95,25.99,26.14,27.47,27.8,27.45,26.24,25.91,26.43,26,25.38,25.04,24.86,25.33,24.52,24.905,24.78,24.8,24.29,24.46,23.469,23.07,22.82,22.96,23.225,22.895,22.51,22.82,23.51,23.59,22.96,24.2,24.48,24.43,24.25,23.83,23.942,23.1,24,24.27,23.79,23.79,23.52,23.92,24.245,25.43,25.54,24.082,24.5,24.34,24.755,25.749,25.61,25.02,25.76,24.74,25.18,24.86,25.04,24.1,23.93,23.831,23.565,23.54,23.1,23.18,22.59,21.975,22.04,22.21,22.21,22.765,23.045,22.67,22.59,22.41,22.49,22,21.92,22.072,22.06,22.3,22.29,21.98,21.95,20.862,21.21,21.315,21.42,21.91,24.765,25.27,27.35,27.19,27.13,26.5,26.3,25.66,23.96,23.875,24.23,24.72,24.715,24.8,24.501,24.19,24.35,24.3,25.08,25.12,24.19,24.73,24.24,24.44,24,23.74,22.92,22.615,22.39,22.59,22.149,22,21.525,21.23,21,20.99,21.245,23.1,22.77,21.49,21.58,21.48,21.43,20.96,20.42,20.42,19.68,19.48,19.35,19.08,18.98,18.75,18.9,19.47,20.1,19.43,19.41,19.4,19.16,19.43,19.16,19.21,19.48,19.92,21.06,20.92,20.75,20.46,20.44,20.1,20.16,20.58,20.83,20.899,20.55,20.42,20.19,20.56,21.43,22.23,22.53,23.225,24.6,25.66,25.15,24.48,24.23,23.96,23.726,22.455,22.29,23.1,23,22.65,22.67,22.94,22.79,22.85,23.09,23.5,23.49,23.97,23.99,23.53,23,21.97,22.69,22.98,22.5,22.78,22.41,22.4,22.84,22.71,22.29,22.465,22.23,22.14,21.65,22.35,22.83,23.27,22.63,22.84,23.36,24.2,24.26,23.3,23.53,23.73,23.92,23.98,22.905,22.19,22.71,22.95,22.33,22.88,23.15,23.49,23.879,23.78,23.91,23.25,23.41,23.49,24.31,24.89,24.11,24.13,24.535,24.96,24.92,24.98,25.13,25.19,24.96,24.88,25.04,24.94,24.89,24.429,23.84,25.17,25.33,25.18,25.63,25.66,25.77,25.735,25.14,24.06,24.48,24.75,24.69,23.62,22.75,22.59,23.11,22.98,22.95,22.27,22.685,22.48,22.34,22.8,23.26,23.1,23.34,23.185,22.762,22.42,22.32],"low":[18.52,18.23,18.14,16.85,16.61,16.54,16.6,15.81,16.035,16.39,16.45,16.64,16.63,16.826,17.17,17.18,17.61,17.64,17.57,17.87,17.685,17.35,17.15,17.01,16.2,15.84,15.9,15.49,16.11,16.64,16.01,16.18,15.425,14.72,13.97,13.95,14.115,13.42,13.5,13.86,13.89,16.83,17.48,16.88,16.79,17.1,16.385,15.69,16.04,16.57,16.86,17.06,17.31,17.09,17.774,17.95,18.14,18.45,18.52,19.355,19.58,20.72,20.54,19.7,20.47,20.54,20.855,21.17,20.9,20.73,20.61,19.8,18.94,17.91,17.7,17.14,17.58,18.36,18.97,19.47,19.17,19.13,19.83,20.97,21.92,22.86,23.06,23.37,22.84,22.71,22.9,22.76,22.23,21.8,21.61,22.19,22.24,22.6,22.64,22.797,23.25,23.41,23,22.635,22.575,21.1,20.73,20.878,21.013,21.37,21.38,22,21.205,20.7,21.06,21.065,21.53,22.09,22.07,22.09,22.43,22.29,22.5,22.37,22.37,22.598,23.064,23.46,23.67,24.48,24.44,24.07,24.1,24.21,23.88,23.22,22.75,23.21,23.06,23.3,23.66,23.87,24.197,24.52,23.72,24.01,24.19,23.98,23.66,23.53,23.16,22.81,22.79,21.12,20.31,20.244,20.26,20.52,19.55,19.56,19.92,19.38,19.31,19,19.95,20.067,20.16,20.02,19.43,19.1,18.82,18.88,18.8,19.36,19.26,19.02,19.643,20.08,19.46,19.8,20.02,19.65,19.805,18.88,19.427,19.61,19.8,19.61,19.68,19.85,19.83,19.755,19.56,19.67,20.29,20.4,20.59,20.95,20.81,20.59,20.63,20.74,20.9,21.25,21.29,21.03,20.915,21.06,20.162,20.28,20.636,20.49,20.7,21,21.18,21.25,21.5,21.22,21.18,20.822,20.19,20.57,20.51,20.57,20.71,21.12,19.82,19.66,19.02,19.46,19.84,20.555,20.58,19.75,19.75,19.78,19.49,20.01,21.62,21.7,21.08,20.6,19.88,19.54,19.14,19.01,19.05,19.265,19.65,18.9,19.22,19.22,18.83,18.56,19.09,19.18,18.879,19.01,19.14,19.04,19.12,19.46,19.15,18.48,18.33,18.158,17.37,17.59,17.53,17.46,17.41,16.94,16.79,16.225,16.25,16.19,16.28,16.325,16.36,16.76,16.82,16.34,16.48,16.6,16.65,16.51,16.77,17.03,16.84,16.91,15.26,15.45,15.805,15.63,15.02,15.09,15.07,15.28,15.26,15.345,16.25,16.36,16.15,16.32,16.15,16.05,15.91,16.29,16.47,16.37,16.46,16.4,16.055,16.65,17.07,17.165,16.83,16.93,17.48,17.47,17.68,17.77,17.5,17.769,17.96,18.18,18.35,18.534,18.7,18.04,17.54,17.57,17.24,16.93,16.695,17.573,18.43,18.49,18.18,17.36,18.45,19.7,20.075,19.78,19.665,19.65,19.08,17.92,17.445,17.455,17.76,17.08,16.93,17.1,17.46,17.7,18.35,18.13,18.86,19.25,19.17,19.81,19.99,20.36,21.22,21.13,21.08,19.99,19.33,18.46,17.91,17.7,18.29,18.38,19.08,18.925,18.32,17.01,16.87,17.05,15.24,14.48,14.17,13.67,13.9,14.24,14.86,14.42,15.41,15.395,15.65,16.71,16.75,16.95,16.29,15.95,16.3,16.76,17.54,17.66,17.78,17.54,18.02,18.08,18.14,18.78,22.49,23.33,24.41,24.54,25.82,26.28,26.02,25.86,24.65,23.96,24.01,24.98,25.51,25,25.18,25.67,26.81,25.88,24.16,24.6,25.59,24.87,24.78,24.42,24.2,24.15,23.43,24.16,23.87,24.04,23.56,23.14,22.46,21.89,22.19,22.48,22.52,21.61,21.7,21.8,22.59,22.44,22.39,22.37,23.57,23.87,23.25,23.12,22.69,22.45,22.64,23.34,23.32,22.94,22.7,23.29,23.65,24.26,23.84,22.8,23.8,23.81,23.97,24.77,24.715,24.39,24.655,24.09,24.53,24.21,23.73,23.45,22.93,23.23,22.9,22.705,22.43,22.25,21.605,21.2,21.365,21.62,21.75,22.119,22.25,22.245,22.11,22.13,21.37,21.46,21.38,21.405,21.525,21.53,21.54,21.37,20.67,19.84,20.14,20.75,20.857,20.96,22.42,24.53,25.25,26.26,26.39,25.43,25.26,23.545,22.98,23.08,23.44,23.7,24,24.335,23.37,23.65,23.475,23.61,23.98,23.7,23.885,23.75,23.4,23.02,23.17,22.43,22.22,21.76,21.64,21.92,21.54,21.5,20.91,20.62,19.77,20.16,20.63,21.54,21.97,20.27,20.568,20.47,20.23,20.17,19.87,19.56,18.9,19.05,18.81,18.19,18.18,18.3,18.5,18.52,18.76,18.855,18.8,18.76,18.81,18.79,18.77,18.59,18.67,19.17,20.05,20.105,20.15,19.917,19.77,19.26,19.77,19.81,20.48,20.12,20,20.12,19.765,19.82,20.59,21.15,21.88,22.46,23.52,24.17,24.3,23.57,23.43,23.48,21.35,21.27,21.13,22.22,22.19,21.58,21.81,22.1,21.79,22.22,22.51,22.74,22.65,23.16,22.89,22.827,21.552,21.26,21.71,21.77,21.81,22.141,21.78,21.29,22.2,21.79,21.442,21.64,21.84,21.31,20.86,21.08,21.93,22.11,21.92,21.99,22.5,23.09,23.25,22.68,22.7,22.9,23.33,22.72,21.86,21.24,21.6,21.9,21.425,22.29,22.57,22.7,23.25,23.22,23.29,22.7,22.67,22.97,23.33,23.91,23.39,23.56,23.52,24.3,24.25,24.4,24.62,24.47,24.25,24.465,24.49,24.49,23.66,23.76,22.78,23.08,24.72,24.1,24.47,25.15,24.94,25.09,24.32,23.25,23.58,24.16,23.63,22.255,22.2,22.2,22.5,22.37,22.11,21.68,22.2,21.7,21.65,22.24,22.52,22.795,22.71,22.56,22.16,21.89,21.73],"close":[18.62,18.55,18.8,17.34,16.7,16.71,16.97,15.87,16.67,16.44,16.89,16.76,16.87,17.18,17.2,17.63,17.72,17.84,17.94,18.18,17.84,17.62,17.35,17.47,16.22,15.94,16.24,15.9,16.92,17.01,16.52,16.27,15.45,14.82,13.98,14.64,14.38,13.65,14.13,13.87,14.95,17.41,17.81,16.96,17.31,17.12,16.67,15.93,16.65,16.76,17.45,17.92,17.7,17.67,18.1,18.07,18.77,18.82,19.72,19.66,20.31,21.5,20.56,21.1,20.54,21.36,20.98,21.8,21.29,21.03,20.84,20.18,19.17,18.4,17.72,17.47,18.95,19.26,19.44,19.67,19.93,19.6,20.73,21.9,23.28,23.67,24.07,23.76,22.86,24.05,22.93,22.82,22.65,22.11,22.12,22.64,23.27,23.07,23.13,23.3,23.57,23.59,23.21,22.78,22.6,21.22,21.27,20.98,21.68,22.05,22.3,22.26,21.35,21.24,21.22,21.52,22.37,22.49,22.82,22.39,22.89,22.56,22.86,22.81,23.13,23.04,23.54,23.59,24.71,24.76,24.53,24.14,24.32,24.38,24.28,23.22,23.2,23.6,23.24,23.63,23.8,24.3,24.73,24.75,24.08,24.58,24.45,24.03,24.19,23.57,23.2,23.01,22.85,21.36,20.9,20.61,21.4,20.55,20,20.55,19.99,19.66,19.34,20.19,20.78,20.65,20.31,20.32,19.64,19.76,18.93,19.13,19.33,19.79,19.33,19.61,20.43,20.51,19.77,20.36,20.03,19.8,19.98,19.59,19.6,20.5,19.81,19.9,20.2,19.87,19.99,20.05,19.91,19.7,20.66,20.77,20.97,21.14,21.37,20.74,21.14,20.85,21.45,21.37,21.5,21.18,21.33,21.12,20.45,20.99,20.94,20.91,20.98,21.42,21.48,21.71,22.13,21.27,21.49,20.91,20.71,20.63,20.8,21.01,21.2,21.27,20.39,19.79,19.77,20.24,20.45,21,20.64,19.77,20.19,19.9,19.94,21.72,22.65,21.76,21.5,20.62,20.05,19.66,19.15,19.32,19.48,19.85,19.92,19.34,19.52,19.27,19,19.26,19.41,19.26,19.24,19.3,19.37,19.27,19.57,19.56,19.29,18.53,18.92,18.33,17.995,17.685,17.74,17.93,17.935,17.035,16.82,16.515,16.275,16.53,16.52,16.38,16.79,16.78,17,16.42,16.82,16.76,16.7,16.86,17.25,17.24,16.94,17.38,15.45,16.01,16.09,15.68,15.15,15.15,15.77,15.55,15.34,16.37,16.66,16.51,16.23,16.53,16.49,16.35,16.28,16.78,16.65,16.57,16.63,16.7,16.67,17.67,17.15,17.36,16.83,17.72,17.61,17.65,17.82,18.2,17.92,17.88,18.37,18.51,18.8,18.75,18.89,18.13,17.72,17.62,17.66,17.01,17.555,18.675,18.95,18.63,18.32,18.47,19.65,20.395,20.44,19.82,19.76,19.72,19.57,18.02,17.74,17.88,17.78,17.2,17.2,17.48,17.6,18.43,18.63,19.02,19.21,19.39,20.1,20.25,20.77,21.23,21.8,21.48,21.09,20.18,19.4,18.69,18.42,18.59,19.29,18.74,19.89,19.18,18.65,17.71,18.39,17.32,15.25,16.77,14.46,14.76,14.68,15.17,15.15,15.34,15.85,15.77,17.28,17.23,17.77,17.22,16.46,16.65,16.52,17.67,17.61,18.63,18.02,17.78,18.65,18.22,18.53,19.44,23.575,24.56,24.72,26.37,26.53,27.37,26.62,26.065,24.695,24.1,25.63,25.29,26.19,25.3,26,27.42,26.86,26.53,24.755,25.76,25.69,24.88,25,24.62,24.62,24.32,24.4,24.33,24.71,24.135,24.27,23.17,22.58,22.37,22.61,22.625,23.13,21.62,22.39,22.8,23.42,22.48,22.47,24.18,24.17,23.9,23.45,23.79,22.88,22.73,23.74,23.5,23.48,23.14,23.37,23.915,24.18,24.94,23.86,23.8,24.37,24.12,24.6,25.6,24.79,24.86,24.98,24.59,24.745,24.36,23.86,23.78,23.09,23.69,23.45,23.05,22.81,22.36,21.73,21.67,21.86,22.03,21.98,22.71,22.56,22.39,22.455,22.25,21.64,21.94,21.47,21.77,21.63,22.22,21.58,21.91,20.73,20.67,20.705,21.14,20.89,21.73,24.73,25.13,26.63,26.94,26.8,25.81,25.61,23.72,23.24,23.84,23.73,24.5,24.45,24.54,23.4,23.98,23.51,23.855,24.795,23.91,23.98,24,23.58,23.42,23.23,22.57,22.27,21.79,21.83,22.29,21.9,21.65,20.95,20.92,20.48,20.61,21.09,22.59,22.16,20.71,21,21.23,20.7,20.24,20.16,19.65,19.27,19.255,19,18.91,18.39,18.42,18.73,19.41,19.16,19.16,19.33,18.84,18.98,18.85,19.12,18.77,19.35,19.87,20.56,20.82,20.19,20.17,19.95,20.07,20.09,20.555,20.71,20.41,20.11,20.21,20.07,20.53,21.37,21.86,22.49,22.82,24.15,25.22,24.37,23.78,23.725,23.59,22.22,21.32,22.14,22.82,22.46,22.32,22.3,22.21,22.22,22.56,22.88,22.91,23.17,23.81,22.95,23.03,22.07,21.91,21.94,22.86,22.26,22.21,22.01,22.215,22.66,21.96,21.66,22.3,22.01,21.33,21.31,22.33,22.1,22.2,22.21,22.82,23.28,24.17,23.57,23.15,22.86,23.4,23.62,22.72,21.87,22.05,22.69,22.08,21.97,22.59,23.12,23.48,23.33,23.42,23.36,23.12,23.03,23.42,24.05,23.95,23.59,23.74,24.51,24.67,24.66,24.73,24.86,24.63,24.75,24.69,24.62,24.76,23.81,23.97,23.22,25.11,24.95,24.69,25.16,25.45,25.56,25.24,24.34,23.6,24.33,24.46,23.68,22.36,22.4,22.48,22.55,22.89,22.33,22.19,22.37,22.06,22.21,22.78,22.95,22.98,22.76,22.64,22.43,22.13,22.31],"lastOpen":22.059999465942383,"lastHigh":22.31999969482422,"lastLow":21.729999542236328,"lastClose":22.309999465942383,"lastVolume":1133152,"lastDate":20210618,"prevClose":22.1299991607666,"afterClose":null,"afterChange":null,"patterns":[{"kind":2,"strength":130.5443,"status":2,"bounces":3,"x1":401,"y1":114,"x2":600,"y2":58,"x3":0,"y3":0,"x4":0,"y4":0,"ticker":""},{"kind":3,"strength":13270.97,"status":-2,"bounces":4,"x1":171,"y1":288,"x2":600,"y2":108,"x3":0,"y3":0,"x4":0,"y4":0,"ticker":""},{"kind":4,"strength":1316.225,"status":-2,"bounces":5,"x1":401,"y1":114,"x2":600,"y2":58,"x3":171,"y3":288,"x4":600,"y4":108,"ticker":""},{"kind":2,"strength":1029.95,"status":2,"bounces":2,"x1":33,"y1":30,"x2":600,"y2":79,"x3":0,"y3":0,"x4":0,"y4":0,"ticker":""}],"patternsMinRange":18,"patternsMaxRange":28};
                                        data.instrument = 'stock';
                                        data.premarket = false;
                                        data.aftermarket = false;
                                        Quote.create(data);
                                    })();
                                  </script><script type="text/javascript">
                                    var chartConfig = {
          "layout":"1h1v",
          "width": 1280,
          "barWidth": 3,
          "barMargin": 1,
          "height": 400,
          "scrollable": false,
          "ideas": false,
          editors: ['publish'],
          "charts":[{
                "height":400,
                "timeframe":"d",
                "scale":"linear",
                "ticker":"EXEL",
                "instrument":"stock",
                "refreshData": 180*1000,
                "panes": []}]
        };
                                    var taConfig = JSON.parse(JSON.stringify(FinvizSettings.TA));

                                    checkSmallDisplay(chartConfig);

                                    
                                    var FinvizQuoteTypeCurrent = taConfig.style;

                                    var mergeChartAndTAConfig = FLibs.Charts.convertTa.mergeChartAndTAConfig;
                                    mergeChartAndTAConfig(chartConfig, taConfig);

                                    var minHeight = 9 /* some browser padding */ + 400 + taConfig.indicators.length * 120 + (chartConfig.ideas ? 40 : 0);
                                    document.getElementById('chart').style.minHeight = minHeight + 'px';

                                    var ChartLayout = FLibs.Charts.ChartLayout;
                                    new ChartLayout({config: chartConfig, el: document.getElementById('chart')});
                                  </script></div><div class="content" data-testid="quote-data-content"><div class="fv-container"><table width="100%"><tr>
<td align="center" valign="top">
<table width="100%" cellpadding="3" cellspacing="0" bgcolor="#ffffff" class="fullview-title">
<tr><td align="center"><a href="quote.ashx?t=EXEL&ty=c&ta=1&p=d" class="fullview-ticker" id="ticker">EXEL</a> <span class="body-table">[NASD]</span></td></tr>
<tr><td align="center"><a href="http://www.exelixis.com" target="_blank" class="tab-link"><b>Exelixis, Inc.</b></a></td></tr>
<tr><td align="center" class="fullview-links"><a href="screener.ashx?v=111&f=sec_healthcare" class="tab-link">Healthcare</a> | <a href="screener.ashx?v=111&f=ind_biotechnology" class="tab-link">Biotechnology</a> | <a href="screener.ashx?v=111&f=geo_usa" class="tab-link">USA</a></td></tr>
</table>
<table width="100%" cellpding="0" cellspacing="0" class="fullview-links">
<td align="left" width="80%">
</td>
<td align="right" width="20%">
<a class="tab-link" href="#statements">statements</a></td>
</tr>
</table>
</tr>
</td>
</table>
<table width="100%" cellpadding="3" cellspacing="0" border="0" class="snapshot-table2">
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Major index membership] offsetx=[10] offsety=[20] delay=[300]">Index</td><td width="8%" class="snapshot-td2" align="left"><b>-</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Price-to-Earnings (ttm)] offsetx=[10] offsety=[20] delay=[300]">P/E</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">110.65</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Diluted EPS (ttm)] offsetx=[10] offsety=[20] delay=[300]">EPS (ttm)</td><td width="8%" class="snapshot-td2" align="left"><b>0.20</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Insider ownership] offsetx=[10] offsety=[20] delay=[300]">Insider Own</td><td width="8%" class="snapshot-td2" align="left"><b>1.70%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Shares outstanding] offsetx=[10] offsety=[20] delay=[300]">Shs Outstand</td><td width="8%" class="snapshot-td2" align="left"><b>312.47M</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Performance (Week)] offsetx=[10] offsety=[20] delay=[300]">Perf Week</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-3.57%</span></b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Market capitalization] offsetx=[10] offsety=[20] delay=[300]">Market Cap</td><td width="8%" class="snapshot-td2" align="left"><b>6.93B</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Forward Price-to-Earnings (next fiscal year)] offsetx=[10] offsety=[20] delay=[300]">Forward P/E</td><td width="8%" class="snapshot-td2" align="left"><b>23.39</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[EPS estimate for next year] offsetx=[10] offsety=[20] delay=[300]">EPS next Y</td><td width="8%" class="snapshot-td2" align="left"><b>0.95</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Insider transactions (6-Month change in Insider Ownership)] offsetx=[10] offsety=[20] delay=[300]">Insider Trans</td><td width="8%" class="snapshot-td2" align="left"><b>-16.68%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Shares float] offsetx=[10] offsety=[20] delay=[300]">Shs Float</td><td width="8%" class="snapshot-td2" align="left"><b>306.58M</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Performance (Month)] offsetx=[10] offsety=[20] delay=[300]">Perf Month</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-9.08%</span></b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Income (ttm)] offsetx=[10] offsety=[20] delay=[300]">Income</td><td width="8%" class="snapshot-td2" align="left"><b>64.80M</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Price-to-Earnings-to-Growth] offsetx=[10] offsety=[20] delay=[300]">PEG</td><td width="8%" class="snapshot-td2" align="left"><b>-</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[EPS estimate for next quarter] offsetx=[10] offsety=[20] delay=[300]">EPS next Q</td><td width="8%" class="snapshot-td2" align="left"><b>0.08</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Institutional ownership] offsetx=[10] offsety=[20] delay=[300]">Inst Own</td><td width="8%" class="snapshot-td2" align="left"><b>85.50%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Short interest share] offsetx=[10] offsety=[20] delay=[300]">Short Float</td><td width="8%" class="snapshot-td2" align="left"><b>3.68%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Performance (Quarter)] offsetx=[10] offsety=[20] delay=[300]">Perf Quarter</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-3.19%</span></b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Revenue (ttm)] offsetx=[10] offsety=[20] delay=[300]">Sales</td><td width="8%" class="snapshot-td2" align="left"><b>1.03B</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Price-to-Sales (ttm)] offsetx=[10] offsety=[20] delay=[300]">P/S</td><td width="8%" class="snapshot-td2" align="left"><b>6.72</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[EPS growth this year] offsetx=[10] offsety=[20] delay=[300]">EPS this Y</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-65.50%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Institutional transactions (3-Month change in Institutional Ownership)] offsetx=[10] offsety=[20] delay=[300]">Inst Trans</td><td width="8%" class="snapshot-td2" align="left"><b>0.71%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Short interest ratio] offsetx=[10] offsety=[20] delay=[300]">Short Ratio</td><td width="8%" class="snapshot-td2" align="left"><b>7.08</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Performance (Half Year)] offsetx=[10] offsety=[20] delay=[300]">Perf Half Y</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">6.29%</span></b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Book value per share (mrq)] offsetx=[10] offsety=[20] delay=[300]">Book/sh</td><td width="8%" class="snapshot-td2" align="left"><b>6.12</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Price-to-Book (mrq)] offsetx=[10] offsety=[20] delay=[300]">P/B</td><td width="8%" class="snapshot-td2" align="left"><b>3.62</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[EPS growth next year] offsetx=[10] offsety=[20] delay=[300]">EPS next Y</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">171.84%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Return on Assets (ttm)] offsetx=[10] offsety=[20] delay=[300]">ROA</td><td width="8%" class="snapshot-td2" align="left"><b>3.10%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Analysts' mean target price] offsetx=[10] offsety=[20] delay=[300]">Target Price</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">31.15</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Performance (Year)] offsetx=[10] offsety=[20] delay=[300]">Perf Year</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-1.56%</span></b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Cash per share (mrq)] offsetx=[10] offsety=[20] delay=[300]">Cash/sh</td><td width="8%" class="snapshot-td2" align="left"><b>3.79</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Price to cash per share (mrq)] offsetx=[10] offsety=[20] delay=[300]">P/C</td><td width="8%" class="snapshot-td2" align="left"><b>5.84</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Long term annual growth estimate (5 years)] offsetx=[10] offsety=[20] delay=[300]">EPS next 5Y</td><td width="8%" class="snapshot-td2" align="left"><b>-</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Return on Equity (ttm)] offsetx=[10] offsety=[20] delay=[300]">ROE</td><td width="8%" class="snapshot-td2" align="left"><b>3.50%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[52-Week trading range] offsetx=[10] offsety=[20] delay=[300]">52W Range</td><td width="8%" class="snapshot-td2" align="left"><b><small>18.18 - 27.35</small></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Performance (Year To Date)] offsetx=[10] offsety=[20] delay=[300]">Perf YTD</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">10.26%</span></b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Dividend (annual)] offsetx=[10] offsety=[20] delay=[300]">Dividend</td><td width="8%" class="snapshot-td2" align="left"><b>-</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Price to Free Cash Flow (ttm)] offsetx=[10] offsety=[20] delay=[300]">P/FCF</td><td width="8%" class="snapshot-td2" align="left"><b>45.69</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Annual EPS growth past 5 years] offsetx=[10] offsety=[20] delay=[300]">EPS past 5Y</td><td width="8%" class="snapshot-td2" align="left"><b>19.70%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Return on Investment (ttm)] offsetx=[10] offsety=[20] delay=[300]">ROI</td><td width="8%" class="snapshot-td2" align="left"><b>4.80%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Distance from 52-Week High] offsetx=[10] offsety=[20] delay=[300]">52W High</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-18.43%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Beta] offsetx=[10] offsety=[20] delay=[300]">Beta</td><td width="8%" class="snapshot-td2" align="left"><b>1.08</b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Dividend yield (annual)] offsetx=[10] offsety=[20] delay=[300]">Dividend %</td><td width="8%" class="snapshot-td2" align="left"><b>-</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Quick Ratio (mrq)] offsetx=[10] offsety=[20] delay=[300]">Quick Ratio</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">6.60</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Annual sales growth past 5 years] offsetx=[10] offsety=[20] delay=[300]">Sales past 5Y</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">92.70%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Gross Margin (ttm)] offsetx=[10] offsety=[20] delay=[300]">Gross Margin</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">96.10%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Distance from 52-Week Low] offsetx=[10] offsety=[20] delay=[300]">52W Low</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">22.72%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Average True Range (14)] offsetx=[10] offsety=[20] delay=[300]">ATR</td><td width="8%" class="snapshot-td2" align="left"><b>0.69</b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Full time employees] offsetx=[10] offsety=[20] delay=[300]">Employees</td><td width="8%" class="snapshot-td2" align="left"><b>773</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Current Ratio (mrq)] offsetx=[10] offsety=[20] delay=[300]">Current Ratio</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">6.70</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Quarterly revenue growth (yoy)] offsetx=[10] offsety=[20] delay=[300]">Sales Q/Q</td><td width="8%" class="snapshot-td2" align="left"><b>19.10%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Operating Margin (ttm)] offsetx=[10] offsety=[20] delay=[300]">Oper. Margin</td><td width="8%" class="snapshot-td2" align="left"><b>5.10%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Relative Strength Index] offsetx=[10] offsety=[20] delay=[300]">RSI (14)</td><td width="8%" class="snapshot-td2" align="left"><b>41.61</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Volatility (Week, Month)] offsetx=[10] offsety=[20] delay=[300]">Volatility</td><td width="8%" class="snapshot-td2" align="left"><b><small>2.40% 3.02%</small></b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Stock has options trading on a market exchange] offsetx=[10] offsety=[20] delay=[300]">Optionable</td><td width="8%" class="snapshot-td2" align="left"><b>Yes</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Total Debt to Equity (mrq)] offsetx=[10] offsety=[20] delay=[300]">Debt/Eq</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">0.00</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Quarterly earnings growth (yoy)] offsetx=[10] offsety=[20] delay=[300]">EPS Q/Q</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-96.80%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Net Profit Margin (ttm)] offsetx=[10] offsety=[20] delay=[300]">Profit Margin</td><td width="8%" class="snapshot-td2" align="left"><b>6.30%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Relative volume] offsetx=[10] offsety=[20] delay=[300]">Rel Volume</td><td width="8%" class="snapshot-td2" align="left"><b>0.78</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Previous close] offsetx=[10] offsety=[20] delay=[300]">Prev Close</td><td width="8%" class="snapshot-td2" align="left"><b>22.13</b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Stock available to sell short] offsetx=[10] offsety=[20] delay=[300]">Shortable</td><td width="8%" class="snapshot-td2" align="left"><b>Yes</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Long Term Debt to Equity (mrq)] offsetx=[10] offsety=[20] delay=[300]">LT Debt/Eq</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">0.00</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Earnings date<br><br>BMO = Before Market Open<br>AMC = After Market Close] offsetx=[10] offsety=[20] delay=[300]">Earnings</td><td width="8%" class="snapshot-td2" align="left"><b>May 06 AMC</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Dividend Payout Ratio (ttm)] offsetx=[10] offsety=[20] delay=[300]">Payout</td><td width="8%" class="snapshot-td2" align="left"><b>0.00%</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Average volume (3 month)] offsetx=[10] offsety=[20] delay=[300]">Avg Volume</td><td width="8%" class="snapshot-td2" align="left"><b>1.59M</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Current stock price] offsetx=[10] offsety=[20] delay=[300]">Price</td><td width="8%" class="snapshot-td2" align="left"><b>22.31</b></td>
</tr>
<tr class="table-dark-row">
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Analysts' mean recommendation (1=Buy 5=Sell)] offsetx=[10] offsety=[20] delay=[300]">Recom</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">1.90</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Distance from 20-Day Simple Moving Average] offsetx=[10] offsety=[20] delay=[300]">SMA20</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-1.93%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Distance from 50-Day Simple Moving Average] offsetx=[10] offsety=[20] delay=[300]">SMA50</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-5.88%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Distance from 200-Day Simple Moving Average] offsetx=[10] offsety=[20] delay=[300]">SMA200</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-red">-0.63%</span></b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Volume] offsetx=[10] offsety=[20] delay=[300]">Volume</td><td width="8%" class="snapshot-td2" align="left"><b>1,133,152</b></td>
<td width="7%" class="snapshot-td2-cp" align="left" title="cssbody=[tooltip_short_bdy] cssheader=[tooltip_short_hdr] body=[Performance (today)] offsetx=[10] offsety=[20] delay=[300]">Change</td><td width="8%" class="snapshot-td2" align="left"><b><span class="is-green">0.81%</span></b></td>
</tr>
</table>
</td>
</tr>
</table>
<tr>
<td>
<table width="100%" cellpadding="0" cellspacing="0" border="0">
<tr><td style="height:10px;font-size:0"><img src="gfx/nic2x2.gif" style="width:685px;height:10px"></td></tr>
<tr><td align="center"><div id="IC_D_3x6_1"></div></td></tr><tr><td style="height:10px;font-size:0"><img src="gfx/nic2x2.gif" style="width:685px;height:10px"></td></tr>
<tr>
<td>
<table width="100%" class="fullview-ratings-outer" cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Jun-15-21</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">H.C. Wainwright</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$47</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">May-18-21</td><td width="200" align="left"><b>Resumed</b></td>
<td width="250" align="left">Goldman</td>
<td width="250" align="left">Sell</td>
<td width="150" align="left">$23</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Mar-31-21</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">Credit Suisse</td>
<td width="250" align="left">Outperform</td>
<td width="150" align="left">$30</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Mar-12-21</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">Wolfe Research</td>
<td width="250" align="left">Outperform</td>
<td width="150" align="left">$35</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Mar-04-20</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">Barclays</td>
<td width="250" align="left">Overweight</td>
<td width="150" align="left">$26</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Jan-13-20</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">SunTrust</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$31</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Nov-13-19</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">BofA/Merrill</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$22</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-upgrade"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-upgrade"><td width="120" align="left">Mar-18-19</td><td width="200" align="left"><b>Upgrade</b></td>
<td width="250" align="left">Morgan Stanley</td>
<td width="250" align="left">Underweight &rarr; Equal-Weight</td>
<td width="150" align="left"></td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Sep-17-18</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">Goldman</td>
<td width="250" align="left">Neutral</td>
<td width="150" align="left">$22</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Sep-10-18</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">Morgan Stanley</td>
<td width="250" align="left">Underweight</td>
<td width="150" align="left">$19</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">May-11-18</td><td width="200" align="left"><b>Reiterated</b></td>
<td width="250" align="left">Needham</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$33 &rarr; $30</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Oct-17-17</td><td width="200" align="left"><b>Reiterated</b></td>
<td width="250" align="left">RBC Capital Mkts</td>
<td width="250" align="left">Outperform</td>
<td width="150" align="left">$33 &rarr; $39</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Oct-17-17</td><td width="200" align="left"><b>Reiterated</b></td>
<td width="250" align="left">Needham</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$30 &rarr; $33</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Oct-16-17</td><td width="200" align="left"><b>Reiterated</b></td>
<td width="250" align="left">SunTrust</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$32 &rarr; $35</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-downgrade"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-downgrade"><td width="120" align="left">Sep-22-17</td><td width="200" align="left"><b>Downgrade</b></td>
<td width="250" align="left">Leerink Partners</td>
<td width="250" align="left">Outperform &rarr; Mkt Perform</td>
<td width="150" align="left"></td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Sep-15-17</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">RBC Capital Mkts</td>
<td width="250" align="left">Outperform</td>
<td width="150" align="left">$32</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Sep-12-17</td><td width="200" align="left"><b>Reiterated</b></td>
<td width="250" align="left">Needham</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$28 &rarr; $30</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Jul-14-17</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">SunTrust</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$33</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Mar-31-17</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">Needham</td>
<td width="250" align="left">Buy</td>
<td width="150" align="left">$28</td>
</tr>
</table>
</td>
</tr>
<tr class="body-table-rating-neutral"><td class="fullview-ratings-inner"><table cellpadding="0" cellspacing="0" border="0">
<tr class="body-table-rating-neutral"><td width="120" align="left">Mar-16-17</td><td width="200" align="left"><b>Initiated</b></td>
<td width="250" align="left">Oppenheimer</td>
<td width="250" align="left">Perform</td>
<td width="150" align="left"></td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr><td style="height:10px;font-size:0"><img src="gfx/nic2x2.gif" style="width:685px;height:10px"></td></tr>
<tr>
<td>
<table width="100%" cellpadding="0" cellspacing="0"><tr><td><table width="100%" cellpadding="1" cellspacing="0" border="0" id="news-table" class="fullview-news-outer">
<tr><td width="130" align="right" style="white-space:nowrap">Jun-18-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-chief-medical-officer-gisela-120000887.html" target="_blank" class="tab-link-news">Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">05:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/06/18/the-smartest-stocks-to-buy-with-100-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">The Smartest Stocks to Buy With $100 Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jun-15-21 11:39AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-bristol-myers-team-153903896.html" target="_blank" class="tab-link-news">Exelixis (EXEL) &amp; Bristol Myers Team Up for Genitourinary Cancers</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jun-14-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-clinical-trial-collaboration-120000255.html" target="_blank" class="tab-link-news">Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jun-07-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-ipsen-announce-detailed-results-120000503.html" target="_blank" class="tab-link-news">Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jun-06-21 10:06AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/06/06/heres-what-crushed-exelixis-earnings/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Here's What Crushed Exelixis' Earnings</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jun-04-21 09:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-quality-adjusted-survival-130000004.html" target="_blank" class="tab-link-news">Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYXÂ® (cabozantinib) in Combination with OPDIVOÂ® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">09:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-positive-phase-2-130000287.html" target="_blank" class="tab-link-news">Exelixis Announces Positive Phase 2 Results for CABOMETYXÂ® (cabozantinib) in Combination with OPDIVOÂ® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">09:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-consistent-efficacy-benefits-130000291.html" target="_blank" class="tab-link-news">Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYXÂ® (cabozantinib) in Combination with OPDIVOÂ® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-30-21 06:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/05/30/2-top-biotech-stocks-to-buy-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">2 Top Biotech Stocks to Buy Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-26-21 04:15PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-webcast-fireside-chats-part-201500827.html" target="_blank" class="tab-link-news">Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">06:06AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/05/26/the-best-stocks-to-invest-3000-in-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">The Best Stocks to Invest $3,000 in Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-25-21 10:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-reports-encouraging-data-145102619.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span> <span class="body-table-news-loss">-5.57%</span></div></div></td></tr>
<tr><td width="130" align="right">07:48AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-cabometyx-roches-tecentriq-combo-114855609.html" target="_blank" class="tab-link-news">Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Benzinga</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-24-21 04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-phase-1b-results-200500701.html" target="_blank" class="tab-link-news">Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-22-21 06:30AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/05/22/is-exelixis-a-buy/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Is Exelixis a Buy?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-21-21 06:31AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/05/21/what-investors-should-look-for-with-exelixis-dermt/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">What Investors Should Look for With Exelixis, DermTech, and Teladoc Health</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-20-21 01:35AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/heres-why-think-exelixis-inc-053551551.html" target="_blank" class="tab-link-news">Here's Why We Think Exelixis, Inc.'s (NASDAQ:EXEL) CEO Compensation Looks Fair</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Simply Wall St.</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-09-21 02:06PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/05/09/why-is-glaxosmithkline-selling-its-income-stream-t/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-07-21 01:04PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-q1-earnings-miss-170405959.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span> <span class="body-table-news-gain">+8.14%</span></div></div></td></tr>
<tr><td width="130" align="right">11:30AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/earnings/call-transcripts/2021/05/07/exelixis-inc-exel-q1-2021-earnings-call-transcript/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right">05:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/05/07/the-smartest-stocks-to-buy-with-50-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">The Smartest Stocks to Buy With $50 Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-06-21 07:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-reports-break-even-230511755.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Reports Break-Even Earnings for Q1</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right">04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-first-quarter-2021-200500049.html" target="_blank" class="tab-link-news">Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">03:15PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-inc-host-earnings-call-191500962.html" target="_blank" class="tab-link-news">Exelixis, Inc. to Host Earnings Call</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> ACCESSWIRE</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">May-04-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-expands-biotherapeutics-portfolio-acquisition-120000879.html" target="_blank" class="tab-link-news">Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharmas First-in-Class Humanized Antibody Program Against a Novel Oncology Target</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-27-21 04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-webcast-fireside-chats-part-200500450.html" target="_blank" class="tab-link-news">Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-26-21 09:29AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exel-stock-buy-sell-132953882.html" target="_blank" class="tab-link-news">Is EXEL Stock A Buy or Sell?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Insider Monkey</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-25-21 06:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/04/25/3-top-biotech-picks-to-buy-and-hold-for-the-next-1/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">3 Top Biotech Picks to Buy and Hold for the Next 10 Years</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-24-21 05:17AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-inc-nasdaq-exel-stock-091747887.html" target="_blank" class="tab-link-news">Exelixis, Inc.'s (NASDAQ:EXEL) Stock Is Going Strong: Have Financials A Role To Play?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Simply Wall St.</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-22-21 04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-release-first-quarter-2021-200500716.html" target="_blank" class="tab-link-news">Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-08-21 05:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/04/08/3-growth-stocks-thatll-make-you-richer-in-q2/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-06-21 12:33PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-ind-oncology-candidate-163304335.html" target="_blank" class="tab-link-news">Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-05-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-u-fda-accepts-120000307.html" target="_blank" class="tab-link-news">Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Apr-01-21 12:21PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-partner-gets-ec-162104259.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right">12:04PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/royalty-pharma-buys-royalty-interest-160421000.html" target="_blank" class="tab-link-news">Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Benzinga</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-31-21 01:01AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-partner-ipsen-receives-european-050100494.html" target="_blank" class="tab-link-news">Exelixis Partner Ipsen Receives European Commission Approval for CABOMETYXÂ® (cabozantinib) in Combination with OPDIVOÂ® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-30-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-enrollment-completion-phase-120000221.html" target="_blank" class="tab-link-news">Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-27-21 06:45AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/03/27/3-exciting-biotech-stocks-to-buy-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">3 Exciting Biotech Stocks to Buy Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-19-21 09:17AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-inks-collaboration-deal-131701194.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right">08:41AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-partners-merck-kgaa-pfizer-124158919.html" target="_blank" class="tab-link-news">Exelixis Partners With Merck KGaA And Pfizer For STELLAR-001 Clinical Trial</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> SmarterAnalyst</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-18-21 09:10AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-xl092-tested-combination-bavencio-131014618.html" target="_blank" class="tab-link-news">Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Benzinga</span></div></div></td></tr>
<tr><td width="130" align="right">08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-clinical-trial-collaboration-120000483.html" target="_blank" class="tab-link-news">Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-12-21 11:30AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/why-exelixis-exel-3-4-163004063.html" target="_blank" class="tab-link-news">Why Is Exelixis (EXEL) Up 3.4% Since Last Earnings Report?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-10-21 03:08AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/introducing-exelixis-nasdaq-exel-stock-080815903.html" target="_blank" class="tab-link-news">Introducing Exelixis (NASDAQ:EXEL), The Stock That Soared 487% In The Last Five Years</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Simply Wall St.</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Mar-08-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-enters-exclusive-license-agreement-130000883.html" target="_blank" class="tab-link-news">Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-26-21 06:30AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-partner-ipsen-receives-positive-113000074.html" target="_blank" class="tab-link-news">Exelixis Partner Ipsen Receives Positive CHMP Opinion for CABOMETYXÂ® (cabozantinib) in Combination with OPDIVOÂ® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-25-21 04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-webcast-fireside-chats-part-210500243.html" target="_blank" class="tab-link-news">Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-breakthrough-therapy-designation-130000204.html" target="_blank" class="tab-link-news">Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-19-21 04:07PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-webcast-virtual-fireside-chat-210700404.html" target="_blank" class="tab-link-news">Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-17-21 06:06AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/02/17/got-500-3-smart-stocks-you-can-buy-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Got $500? 3 Smart Stocks You Can Buy Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-16-21 09:01AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-cabozantinib-data-shows-clinically-140137082.html" target="_blank" class="tab-link-news">Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Benzinga</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-13-21 01:00PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-highlights-positive-results-cabometyx-180000866.html" target="_blank" class="tab-link-news">Exelixis Highlights Positive Results for CABOMETYXÂ® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-12-21 05:15PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-final-phase-1-221500974.html" target="_blank" class="tab-link-news">Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-11-21 03:00PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-q4-earnings-surpass-200008409.html" target="_blank" class="tab-link-news">Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right">07:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/earnings/call-transcripts/2021/02/11/exelixis-inc-exel-q4-2020-earnings-call-transcript/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Exelixis Inc (EXEL) Q4 2020 Earnings Call Transcript</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-10-21 05:55PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-q4-earnings-surpass-225510388.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Q4 Earnings Surpass Estimates</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right">04:40PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/recap-exelixis-q4-earnings-214041584.html" target="_blank" class="tab-link-news">Recap: Exelixis Q4 Earnings</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Benzinga</span></div></div></td></tr>
<tr><td width="130" align="right">04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-fourth-quarter-full-210500481.html" target="_blank" class="tab-link-news">Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">02:45PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-inc-host-earnings-call-194500810.html" target="_blank" class="tab-link-news">Exelixis, Inc. to Host Earnings Call</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> ACCESSWIRE</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-09-21 04:08PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-host-investor-briefing-discuss-210800362.html" target="_blank" class="tab-link-news">Exelixis to Host Investor Briefing to Discuss Data Presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Symposium</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">10:16AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/earnings-outlook-exelixis-151626806.html" target="_blank" class="tab-link-news">Earnings Outlook For Exelixis</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Benzinga</span></div></div></td></tr>
<tr><td width="130" align="right">07:13AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/opdivo-plus-cabometyx-combo-shows-121333822.html" target="_blank" class="tab-link-news">Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Benzinga</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-08-21 05:00PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/opdivo-nivolumab-combination-cabometyx-cabozantinib-220000511.html" target="_blank" class="tab-link-news">OPDIVOÂ® (nivolumab) in Combination with CABOMETYXÂ® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">05:00PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-positive-findings-asco-220000829.html" target="_blank" class="tab-link-news">Exelixis Announces Positive Findings at ASCO GU for CABOMETYXÂ® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">10:01AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-report-q4-earnings-150103824.html" target="_blank" class="tab-link-news">Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-04-21 04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-webcast-virtual-fireside-chat-210500750.html" target="_blank" class="tab-link-news">Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 11, 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-03-21 12:31PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/earnings-preview-exelixis-exel-q4-173105984.html" target="_blank" class="tab-link-news">Earnings Preview: Exelixis (EXEL) Q4 Earnings Expected to Decline</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Feb-01-21 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-adagene-enter-collaboration-license-130000901.html" target="_blank" class="tab-link-news">Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-29-21 05:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/01/29/got-4000-4-growth-stocks-begging-to-be-bought/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Got $4,000? 4 Growth Stocks Begging to Be Bought</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-27-21 04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-release-fourth-quarter-full-210500119.html" target="_blank" class="tab-link-news">Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">11:05AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/biotech-stock-roundup-coronavirus-updates-160504752.html" target="_blank" class="tab-link-news">Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, &amp; Other Updates</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-25-21 09:24AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-wins-fda-nod-142402901.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right">08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-initiation-phase-1-130000617.html" target="_blank" class="tab-link-news">Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-22-21 07:44PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/01/22/exelixis-gets-fda-approval-for-cabometyx-in-combin/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right">01:10PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-u-fda-approval-181000691.html" target="_blank" class="tab-link-news">Exelixis Announces U.S. FDA Approval of CABOMETYXÂ® (cabozantinib) in Combination with OPDIVOÂ® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-11-21 09:48AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-reports-preliminary-q4-144802790.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span> <span class="body-table-news-gain">+5.83%</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-10-21 04:00PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-preliminary-fourth-quarter-210000583.html" target="_blank" class="tab-link-news">Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">06:06AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/01/10/3-top-biotech-picks-for-2021/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">3 Top Biotech Picks for 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-09-21 05:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2021/01/09/5-value-stocks-that-will-make-you-richer-in-2021/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">5 Value Stocks That Will Make You Richer in 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Jan-04-21 04:05PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-present-virtual-39th-annual-210500312.html" target="_blank" class="tab-link-news">Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-31-20 06:05AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2020/12/31/3-healthcare-stocks-that-are-screaming-buys-2021/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">3 Healthcare Stocks That Are Screaming Buys in 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-28-20 01:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/kind-investors-own-most-exelixis-065117412.html" target="_blank" class="tab-link-news">What Kind Of Investors Own Most Of Exelixis, Inc. (NASDAQ:EXEL)?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Simply Wall St.</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-23-20 06:06AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2020/12/23/3-beaten-down-growth-stocks-that-can-soar-in-2021/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">3 Beaten-Down Growth Stocks That Can Soar in 2021</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-22-20 04:37PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exel-good-stock-buy-according-213758048.html" target="_blank" class="tab-link-news">Is EXEL A Good Stock To Buy According To Hedge Funds?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Insider Monkey</span></div></div></td></tr>
<tr><td width="130" align="right">10:39AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-posts-positive-data-153903876.html" target="_blank" class="tab-link-news">Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-21-20 11:55AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2020/12/21/should-investors-buy-this-biotech-takeover-target/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Should Investors Consider This Biotech Takeover Target?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right">07:30AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-cabozantinib-significantly-improved-123000213.html" target="_blank" class="tab-link-news">Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-19-20 06:09AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2020/12/19/3-top-biotech-stocks-to-buy-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">3 Top Biotech Stocks to Buy Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-16-20 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/xwpharma-names-michael-m-morrissey-130000437.html" target="_blank" class="tab-link-news">XWPharma Names Michael M. Morrissey, PhD to Board of Directors</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> GlobeNewswire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-08-20 01:32PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-licenses-aurigenes-compound-183206260.html" target="_blank" class="tab-link-news">Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-07-20 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-licenses-aurigene-novel-cdk7-130000893.html" target="_blank" class="tab-link-news">Exelixis In-Licenses Aurigenes Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-05-20 11:32AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/why-exelixis-exel-down-14-163204866.html" target="_blank" class="tab-link-news">Why Is Exelixis (EXEL) Down 14.4% Since Last Earnings Report?</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Dec-02-20 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-licenses-iconic-therapeutics-tissue-130000818.html" target="_blank" class="tab-link-news">Exelixis In-Licenses Iconic Therapeutics Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Nov-27-20 08:00AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-announces-partner-takeda-receives-130000879.html" target="_blank" class="tab-link-news">Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYXÂ® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right">05:51AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/investing/2020/11/27/got-50-4-smart-stocks-to-buy-into-right-now/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Got $50? 4 Smart Stocks to Buy Into Right Now</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Nov-23-20 05:30PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-webcast-fireside-chats-part-223000410.html" target="_blank" class="tab-link-news">Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Business Wire</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Nov-11-20 08:24AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/strong-sell-stocks-november-11th-132401856.html" target="_blank" class="tab-link-news">New Strong Sell Stocks for November 11th</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
<tr><td width="130" align="right" style="white-space:nowrap">Nov-06-20 03:01PM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://www.fool.com/earnings/call-transcripts/2020/11/06/exelixis-inc-exel-q3-2020-earnings-call-transcript/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article" target="_blank" class="tab-link-news">Exelixis Inc (EXEL) Q3 2020 Earnings Call Transcript</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Motley Fool</span> <span class="body-table-news-loss">-6.54%</span></div></div></td></tr>
<tr><td width="130" align="right">10:33AM&nbsp;&nbsp;</td><td align="left"><div class="news-link-container"><div class="news-link-left"><a href="https://finance.yahoo.com/news/exelixis-exel-q3-loss-wider-153303439.html" target="_blank" class="tab-link-news">Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat</a></div><div class="news-link-right"><span style="color:#aa6dc0;font-size:9px"> Zacks</span></div></div></td></tr>
</table>
</td><td width="300" valign="top" style="padding-left: 10px"><div id="stocktwits-widget-news" class="fullview-news-outer" data-testid="quote-stocktwits-widget-news-container"></div>
                                  <script type="text/javascript" defer src="//stocktwits.com/addon/widget/2/widget-loader.min.js"></script>
                                  <script type="text/javascript">
                                    var StocktwitsHeight = document.getElementById('news-table').clientHeight - (FinvizSettings.hasUserPremium ? 0 : 270);
                                    if (StocktwitsHeight > 700 && !FinvizSettings.hasUserPremium) {
                                        StocktwitsHeight -= 270;
                                        var adDiv = document.createElement('div');
                                        adDiv.id = 'IC_D_300x250_2';
                                        adDiv.style.marginTop = '20px';
                                        var stocktwitsContainer = document.getElementById('stocktwits-widget-news');
                                        stocktwitsContainer.parentNode.insertBefore(adDiv, stocktwitsContainer.nextSibling);
                                    }

                                    function StocktwitsInit() {
                                        if(typeof STWT !== 'undefined') {
                                            var quoteTicker = 'EXEL';
                                            STWT.Widget({
                                                container: 'stocktwits-widget-news',
                                                symbol: quoteTicker,
                                                width: '300',
                                                height: StocktwitsHeight,
                                                limit: '15',
                                                scrollbars: 0,
                                                header: 0,
                                                streaming: 'true',
                                                style: { link_color: '4871a8', link_hover_color: '4871a8', header_text_color: '000000', border_color: 'transparent', border_color_2: 'transparent', divider_color: 'd3d3d3', divider_type: 'solid', box_color: 'transparent', stream_color: 'transparent', text_color: '000000', time_color: '999999', font: 'Verdana, Arial, Tahoma', font_size: 11, time_font_size: 10, username_font: 'Verdana, Arial, Tahoma', username_size: 11 }
                                            });
                                        }
                                    }
                                  </script></td></tr></table></td>
</tr>
<tr><td style="height:10px;font-size:0"><img src="gfx/nic2x2.gif" style="width:685px;height:10px"></td></tr>
<tr class="table-light3-row">
<td class="fullview-profile" align="left">Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.</td></tr>
<tr><td style="height:10px;font-size:0"><img src="gfx/nic2x2.gif" style="width:685px;height:10px"></td></tr>
<tr><td width="100%"><div id="statements"></div></td></tr><tr><td style="height:10px;font-size:0"><img src="gfx/nic2x2.gif" style="width:685px;height:10px"></td></tr>
<tr>
<td>
<table border="0" cellpadding="2" cellspacing="0" width="100%" class="body-table" bgcolor="#d3d3d3">
<tr>
<td class="table-top-w" align="left">Insider Trading</td>
<td class="table-top-w" align="left">Relationship</td>
<td class="table-top-w" align="left">Date</td>
<td class="table-top-w" align="center">Transaction</td>
<td class="table-top-w" align="right">Cost</td>
<td class="table-top-w" align="right">#Shares</td>
<td class="table-top-w" align="right">Value ($)</td>
<td class="table-top-w" align="right">#Shares Total</td>
<td class="table-top-w" align="center">SEC Form 4</td>
</tr>
<tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1692954&tc=7" class="tab-link">Haley Patrick J.</td><td style="white-space:nowrap">EVP, Commercial</td><td>May 18</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">24.73</td><td align="right">14,593</td><td align="right">360,885</td><td align="right">280,994</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000055/xslF345X03/wf-form4_162138317439427.xml" class="tab-link">May 18 08:13 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202095&tc=7" class="tab-link">MARCHESI VINCENT T</td><td style="white-space:nowrap">Director</td><td>May 14</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">6.30</td><td align="right">40,000</td><td align="right">252,000</td><td align="right">106,115</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000053/xslF345X03/wf-form4_162129678672791.xml" class="tab-link">May 17 08:13 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1202095&tc=7" class="tab-link">MARCHESI VINCENT T</td><td style="white-space:nowrap">Director</td><td>May 14</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.04</td><td align="right">40,000</td><td align="right">1,001,600</td><td align="right">66,115</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000053/xslF345X03/wf-form4_162129678672791.xml" class="tab-link">May 17 08:13 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1180770&tc=7" class="tab-link">POSTE GEORGE</td><td style="white-space:nowrap">Director</td><td>May 14</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">24.97</td><td align="right">40,802</td><td align="right">1,018,826</td><td align="right">157,190</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000052/xslF345X03/wf-form4_162129669367535.xml" class="tab-link">May 17 08:11 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>May 13</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.90</td><td align="right">100,000</td><td align="right">190,000</td><td align="right">714,078</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000050/xslF345X03/wf-form4_162103888892358.xml" class="tab-link">May 14 08:35 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>May 13</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.38</td><td align="right">100,000</td><td align="right">2,538,000</td><td align="right">614,078</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000050/xslF345X03/wf-form4_162103888892358.xml" class="tab-link">May 14 08:35 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202096&tc=7" class="tab-link">MORRISSEY MICHAEL</td><td style="white-space:nowrap">President and CEO</td><td>May 12</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">4.20</td><td align="right">50,000</td><td align="right">210,000</td><td align="right">541,813</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000051/xslF345X03/wf-form4_162103985398361.xml" class="tab-link">May 14 08:51 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202098&tc=7" class="tab-link">PAPADOPOULOS STELIOS</td><td style="white-space:nowrap">Director</td><td>May 11</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">4.27</td><td align="right">120,000</td><td align="right">512,400</td><td align="right">1,293,600</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000049/xslF345X03/wf-form4_162095233683684.xml" class="tab-link">May 13 08:32 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1202098&tc=7" class="tab-link">PAPADOPOULOS STELIOS</td><td style="white-space:nowrap">Director</td><td>May 11</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">24.98</td><td align="right">20,770</td><td align="right">518,794</td><td align="right">1,218,675</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000049/xslF345X03/wf-form4_162095233683684.xml" class="tab-link">May 13 08:32 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1547999&tc=7" class="tab-link">Freire Maria C</td><td style="white-space:nowrap">Director</td><td>May 11</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.01</td><td align="right">8,275</td><td align="right">206,958</td><td align="right">31,827</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000054/xslF345X03/wf-form4_162129692660785.xml" class="tab-link">May 17 08:15 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Apr 26</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">50,000</td><td align="right">85,000</td><td align="right">663,482</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000043/xslF345X03/wf-form4_161965500597259.xml" class="tab-link">Apr 28 08:10 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Apr 26</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.00</td><td align="right">50,000</td><td align="right">1,250,000</td><td align="right">613,482</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000043/xslF345X03/wf-form4_161965500597259.xml" class="tab-link">Apr 28 08:10 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1692954&tc=7" class="tab-link">Haley Patrick J.</td><td style="white-space:nowrap">EVP, Commercial</td><td>Apr 26</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.03</td><td align="right">7,665</td><td align="right">191,855</td><td align="right">297,392</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000042/xslF345X03/wf-form4_161965486730408.xml" class="tab-link">Apr 28 08:08 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Apr 26</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.03</td><td align="right">18,000</td><td align="right">450,540</td><td align="right">628,248</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000041/xslF345X03/wf-form4_161965479571792.xml" class="tab-link">Apr 28 08:06 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Apr 01</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">50,000</td><td align="right">85,000</td><td align="right">663,482</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000039/xslF345X03/wf-form4_161740683370551.xml" class="tab-link">Apr 02 07:41 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Apr 01</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">60,000</td><td align="right">102,000</td><td align="right">449,467</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000040/xslF345X03/wf-form4_161740743547342.xml" class="tab-link">Apr 02 07:51 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Apr 01</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">23.00</td><td align="right">50,000</td><td align="right">1,150,000</td><td align="right">613,482</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000039/xslF345X03/wf-form4_161740683370551.xml" class="tab-link">Apr 02 07:41 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Apr 01</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.96</td><td align="right">60,000</td><td align="right">1,377,600</td><td align="right">389,467</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000040/xslF345X03/wf-form4_161740743547342.xml" class="tab-link">Apr 02 07:51 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1023225&tc=7" class="tab-link">WYSZOMIERSKI JACK L</td><td style="white-space:nowrap">Director</td><td>Mar 29</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.38</td><td align="right">40,000</td><td align="right">135,200</td><td align="right">237,809</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000038/xslF345X03/wf-form4_161723893234049.xml" class="tab-link">Mar 31 09:02 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1023225&tc=7" class="tab-link">WYSZOMIERSKI JACK L</td><td style="white-space:nowrap">Director</td><td>Mar 29</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.64</td><td align="right">6,220</td><td align="right">140,821</td><td align="right">231,589</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000038/xslF345X03/wf-form4_161723893234049.xml" class="tab-link">Mar 31 09:02 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1312907&tc=7" class="tab-link">Garber Alan M</td><td style="white-space:nowrap">Director</td><td>Mar 15</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.38</td><td align="right">40,000</td><td align="right">135,200</td><td align="right">52,718</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000037/xslF345X03/wf-form4_161602625006192.xml" class="tab-link">Mar 17 08:11 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1312907&tc=7" class="tab-link">Garber Alan M</td><td style="white-space:nowrap">Director</td><td>Mar 15</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">23.60</td><td align="right">40,000</td><td align="right">944,000</td><td align="right">12,718</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000037/xslF345X03/wf-form4_161602625006192.xml" class="tab-link">Mar 17 08:11 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Mar 01</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">65,000</td><td align="right">110,500</td><td align="right">405,072</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000029/xslF345X03/wf-form4_161481892190996.xml" class="tab-link">Mar 03 07:49 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Mar 01</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.11</td><td align="right">65,000</td><td align="right">1,437,150</td><td align="right">340,072</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000029/xslF345X03/wf-form4_161481892190996.xml" class="tab-link">Mar 03 07:49 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202089&tc=7" class="tab-link">COHEN CHARLES</td><td style="white-space:nowrap">Director</td><td>Feb 24</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.38</td><td align="right">40,000</td><td align="right">135,200</td><td align="right">221,375</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000026/xslF345X03/wf-form4_161438823233506.xml" class="tab-link">Feb 26 08:10 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1202089&tc=7" class="tab-link">COHEN CHARLES</td><td style="white-space:nowrap">Director</td><td>Feb 24</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.69</td><td align="right">40,000</td><td align="right">907,600</td><td align="right">181,375</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000026/xslF345X03/wf-form4_161438823233506.xml" class="tab-link">Feb 26 08:10 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202106&tc=7" class="tab-link">WILLSEY LANCE</td><td style="white-space:nowrap">Director</td><td>Feb 23</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.38</td><td align="right">40,000</td><td align="right">135,200</td><td align="right">464,415</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000023/xslF345X03/wf-form4_161421549385793.xml" class="tab-link">Feb 24 08:11 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1202106&tc=7" class="tab-link">WILLSEY LANCE</td><td style="white-space:nowrap">Director</td><td>Feb 23</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">21.93</td><td align="right">40,000</td><td align="right">877,136</td><td align="right">424,415</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000023/xslF345X03/wf-form4_161421549385793.xml" class="tab-link">Feb 24 08:11 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1180770&tc=7" class="tab-link">POSTE GEORGE</td><td style="white-space:nowrap">Director</td><td>Feb 22</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.38</td><td align="right">40,000</td><td align="right">135,200</td><td align="right">197,992</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000025/xslF345X03/wf-form4_161421584386456.xml" class="tab-link">Feb 24 08:18 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1202095&tc=7" class="tab-link">MARCHESI VINCENT T</td><td style="white-space:nowrap">Director</td><td>Feb 22</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.29</td><td align="right">24,097</td><td align="right">537,122</td><td align="right">66,115</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000024/xslF345X03/wf-form4_161421570407092.xml" class="tab-link">Feb 24 08:15 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Feb 18</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">50,000</td><td align="right">85,000</td><td align="right">590,597</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000021/xslF345X03/wf-form4_161378260922150.xml" class="tab-link">Feb 19 07:57 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Feb 18</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.35</td><td align="right">50,000</td><td align="right">1,117,500</td><td align="right">540,597</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000021/xslF345X03/wf-form4_161378260922150.xml" class="tab-link">Feb 19 07:57 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Feb 17</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">50,000</td><td align="right">85,000</td><td align="right">590,597</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000021/xslF345X03/wf-form4_161378260922150.xml" class="tab-link">Feb 19 07:57 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1213140&tc=7" class="tab-link">Schwab Gisela</td><td style="white-space:nowrap">Pres, Prod Dev & Med Aff & CMO</td><td>Feb 17</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.50</td><td align="right">50,000</td><td align="right">1,125,000</td><td align="right">540,597</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000021/xslF345X03/wf-form4_161378260922150.xml" class="tab-link">Feb 19 07:57 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1326377&tc=7" class="tab-link">FELDBAUM CARL B</td><td style="white-space:nowrap">Director</td><td>Feb 16</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.38</td><td align="right">20,000</td><td align="right">67,600</td><td align="right">28,521</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000014/xslF345X03/wf-form4_161361018341592.xml" class="tab-link">Feb 17 08:03 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1326377&tc=7" class="tab-link">FELDBAUM CARL B</td><td style="white-space:nowrap">Director</td><td>Feb 16</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">21.96</td><td align="right">20,000</td><td align="right">439,200</td><td align="right">8,521</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000014/xslF345X03/wf-form4_161361018341592.xml" class="tab-link">Feb 17 08:03 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1202106&tc=7" class="tab-link">WILLSEY LANCE</td><td style="white-space:nowrap">Director</td><td>Feb 16</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">21.90</td><td align="right">50,000</td><td align="right">1,095,000</td><td align="right">424,415</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000023/xslF345X03/wf-form4_161421549385793.xml" class="tab-link">Feb 24 08:11 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1692954&tc=7" class="tab-link">Haley Patrick J.</td><td style="white-space:nowrap">EVP, Commercial</td><td>Feb 12</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">21.57</td><td align="right">45,000</td><td align="right">970,650</td><td align="right">246,887</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000020/xslF345X03/wf-form4_161361093670952.xml" class="tab-link">Feb 17 08:15 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Feb 01</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">65,000</td><td align="right">110,500</td><td align="right">348,124</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000007/xslF345X03/wf-form4_161240023597689.xml" class="tab-link">Feb 03 07:57 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Feb 01</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">22.08</td><td align="right">65,000</td><td align="right">1,435,200</td><td align="right">283,124</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000007/xslF345X03/wf-form4_161240023597689.xml" class="tab-link">Feb 03 07:57 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1648367&tc=7" class="tab-link">Senner Christopher J.</td><td style="white-space:nowrap">EVP and CFO</td><td>Jan 12</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.66</td><td align="right">30,000</td><td align="right">109,800</td><td align="right">275,596</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000006/xslF345X03/wf-form4_161067375022456.xml" class="tab-link">Jan 14 08:22 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1648367&tc=7" class="tab-link">Senner Christopher J.</td><td style="white-space:nowrap">EVP and CFO</td><td>Jan 12</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.00</td><td align="right">30,000</td><td align="right">750,000</td><td align="right">245,596</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000006/xslF345X03/wf-form4_161067375022456.xml" class="tab-link">Jan 14 08:22 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Jan 04</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">65,000</td><td align="right">110,500</td><td align="right">348,124</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000002/xslF345X03/wf-form4_160998363690231.xml" class="tab-link">Jan 06 08:40 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Jan 04</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.12</td><td align="right">50,000</td><td align="right">256,100</td><td align="right">541,754</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000001/xslF345X03/wf-form4_160998251861758.xml" class="tab-link">Jan 06 08:22 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Jan 04</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">20.32</td><td align="right">65,000</td><td align="right">1,320,800</td><td align="right">283,124</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976721000002/xslF345X03/wf-form4_160998363690231.xml" class="tab-link">Jan 06 08:40 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Dec 18</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">1.70</td><td align="right">65,000</td><td align="right">110,500</td><td align="right">348,124</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000160/xslF345X03/wf-form4_160868509495790.xml" class="tab-link">Dec 22 07:58 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1387306&tc=7" class="tab-link">Lamb Peter</td><td style="white-space:nowrap">EVP, Scientific Strategy & CSO</td><td>Dec 18</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">20.01</td><td align="right">65,000</td><td align="right">1,300,650</td><td align="right">283,124</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000160/xslF345X03/wf-form4_160868509495790.xml" class="tab-link">Dec 22 07:58 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202106&tc=7" class="tab-link">WILLSEY LANCE</td><td style="white-space:nowrap">Director</td><td>Dec 04</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.82</td><td align="right">106,142</td><td align="right">617,746</td><td align="right">474,415</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000159/xslF345X03/wf-form4_160712977816539.xml" class="tab-link">Dec 04 07:56 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202095&tc=7" class="tab-link">MARCHESI VINCENT T</td><td style="white-space:nowrap">Director</td><td>Nov 24</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.82</td><td align="right">40,004</td><td align="right">232,823</td><td align="right">130,216</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000158/xslF345X03/wf-form4_160635156809212.xml" class="tab-link">Nov 25 07:46 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1202095&tc=7" class="tab-link">MARCHESI VINCENT T</td><td style="white-space:nowrap">Director</td><td>Nov 24</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">18.50</td><td align="right">40,004</td><td align="right">740,074</td><td align="right">90,212</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000158/xslF345X03/wf-form4_160635156809212.xml" class="tab-link">Nov 25 07:46 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Nov 15</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">7.27</td><td align="right">30,000</td><td align="right">218,100</td><td align="right">494,254</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000153/xslF345X03/wf-form4_160566122128587.xml" class="tab-link">Nov 17 08:00 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1023225&tc=7" class="tab-link">WYSZOMIERSKI JACK L</td><td style="white-space:nowrap">Director</td><td>Nov 10</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.82</td><td align="right">62,403</td><td align="right">363,185</td><td align="right">231,809</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000151/xslF345X03/wf-form4_160531670904103.xml" class="tab-link">Nov 13 08:18 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1023225&tc=7" class="tab-link">WYSZOMIERSKI JACK L</td><td style="white-space:nowrap">Director</td><td>Nov 10</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">20.61</td><td align="right">34,000</td><td align="right">700,740</td><td align="right">197,809</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000151/xslF345X03/wf-form4_160531670904103.xml" class="tab-link">Nov 13 08:18 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Oct 21</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">7.27</td><td align="right">39,742</td><td align="right">288,924</td><td align="right">382,768</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000135/xslF345X03/wf-form4_160349809329524.xml" class="tab-link">Oct 23 08:08 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Oct 21</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">21.95</td><td align="right">39,742</td><td align="right">872,337</td><td align="right">343,026</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000135/xslF345X03/wf-form4_160349809329524.xml" class="tab-link">Oct 23 08:08 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1648367&tc=7" class="tab-link">Senner Christopher J.</td><td style="white-space:nowrap">EVP and CFO</td><td>Oct 08</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.66</td><td align="right">10,000</td><td align="right">36,600</td><td align="right">137,882</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000134/xslF345X03/wf-form4_160228823687027.xml" class="tab-link">Oct 09 08:04 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1648367&tc=7" class="tab-link">Senner Christopher J.</td><td style="white-space:nowrap">EVP and CFO</td><td>Oct 08</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.00</td><td align="right">10,000</td><td align="right">250,000</td><td align="right">127,882</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000134/xslF345X03/wf-form4_160228823687027.xml" class="tab-link">Oct 09 08:04 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Sep 22</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">7.27</td><td align="right">10,258</td><td align="right">74,576</td><td align="right">353,284</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000132/xslF345X03/wf-form4_160099218384042.xml" class="tab-link">Sep 24 08:03 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Sep 22</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">26.14</td><td align="right">10,258</td><td align="right">268,144</td><td align="right">343,026</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000132/xslF345X03/wf-form4_160099218384042.xml" class="tab-link">Sep 24 08:03 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1692954&tc=7" class="tab-link">Haley Patrick J.</td><td style="white-space:nowrap">EVP, Commercial</td><td>Sep 21</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.82</td><td align="right">4,680</td><td align="right">27,238</td><td align="right">120,251</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000131/xslF345X03/wf-form4_160090636260752.xml" class="tab-link">Sep 23 08:12 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1692954&tc=7" class="tab-link">Haley Patrick J.</td><td style="white-space:nowrap">EVP, Commercial</td><td>Sep 21</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">26.09</td><td align="right">4,680</td><td align="right">122,101</td><td align="right">115,571</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000131/xslF345X03/wf-form4_160090636260752.xml" class="tab-link">Sep 23 08:12 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Sep 16</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">7.27</td><td align="right">20,000</td><td align="right">145,400</td><td align="right">363,026</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000130/xslF345X03/wf-form4_160030226619984.xml" class="tab-link">Sep 16 08:24 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Sep 16</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">26.11</td><td align="right">20,000</td><td align="right">522,200</td><td align="right">343,026</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000130/xslF345X03/wf-form4_160030226619984.xml" class="tab-link">Sep 16 08:24 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1648367&tc=7" class="tab-link">Senner Christopher J.</td><td style="white-space:nowrap">EVP and CFO</td><td>Sep 15</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">3.66</td><td align="right">20,000</td><td align="right">73,200</td><td align="right">147,882</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000129/xslF345X03/wf-form4_160021461881803.xml" class="tab-link">Sep 15 08:03 PM</a></td></tr><tr class="insider-sale-row-2" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-2'" valign="top"><td><a href="insidertrading.ashx?oc=1648367&tc=7" class="tab-link">Senner Christopher J.</td><td style="white-space:nowrap">EVP and CFO</td><td>Sep 15</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.00</td><td align="right">20,000</td><td align="right">500,000</td><td align="right">127,882</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000129/xslF345X03/wf-form4_160021461881803.xml" class="tab-link">Sep 15 08:03 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1599803&tc=7" class="tab-link">Hessekiel Jeffrey</td><td style="white-space:nowrap">EVP and General Counsel</td><td>Sep 08</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.18</td><td align="right">249,692</td><td align="right">1,293,315</td><td align="right">503,692</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000128/xslF345X03/wf-form4_159978475973402.xml" class="tab-link">Sep 10 08:39 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202089&tc=7" class="tab-link">COHEN CHARLES</td><td style="white-space:nowrap">Director</td><td>Sep 01</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.82</td><td align="right">115,396</td><td align="right">671,605</td><td align="right">181,375</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000121/xslF345X03/wf-form4_159917791684326.xml" class="tab-link">Sep 03 08:05 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1180770&tc=7" class="tab-link">POSTE GEORGE</td><td style="white-space:nowrap">Director</td><td>Aug 14</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">5.82</td><td align="right">29,662</td><td align="right">172,633</td><td align="right">157,992</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000120/xslF345X03/wf-form4_159744901922438.xml" class="tab-link">Aug 14 07:50 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202096&tc=7" class="tab-link">MORRISSEY MICHAEL</td><td style="white-space:nowrap">President and CEO</td><td>Jul 20</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">6.21</td><td align="right">100,000</td><td align="right">621,000</td><td align="right">185,985</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000107/xslF345X03/wf-form4_159545916437063.xml" class="tab-link">Jul 22 07:06 PM</a></td></tr><tr class="insider-sale-row-1" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-sale-row-1'" valign="top"><td><a href="insidertrading.ashx?oc=1692954&tc=7" class="tab-link">Haley Patrick J.</td><td style="white-space:nowrap">EVP, Commercial</td><td>Jul 20</td><td style="white-space:nowrap" align="center">Sale</td><td align="right">25.36</td><td align="right">3,151</td><td align="right">79,909</td><td align="right">112,189</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000106/xslF345X03/wf-form4_159545890192637.xml" class="tab-link">Jul 22 07:01 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202096&tc=7" class="tab-link">MORRISSEY MICHAEL</td><td style="white-space:nowrap">President and CEO</td><td>Jul 10</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">6.21</td><td align="right">100,000</td><td align="right">621,000</td><td align="right">185,985</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000105/xslF345X03/wf-form4_159442849992411.xml" class="tab-link">Jul 10 08:48 PM</a></td></tr><tr class="insider-option-row" onmouseover="this.className='insider-light-row-h'" onmouseout="this.className='insider-option-row'" valign="top"><td><a href="insidertrading.ashx?oc=1202096&tc=7" class="tab-link">MORRISSEY MICHAEL</td><td style="white-space:nowrap">President and CEO</td><td>Jun 19</td><td style="white-space:nowrap" align="center">Option Exercise</td><td align="right">6.21</td><td align="right">100,000</td><td align="right">621,000</td><td align="right">185,985</td><td style="white-space:nowrap" align="center"><a href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000104/xslF345X03/wf-form4_159261599241441.xml" class="tab-link">Jun 19 09:20 PM</a></td></tr></table>
</td>
</tr>
<table  style="margin: 21px auto 14px auto" cellpadding="0" cellspacing="0" border="0">
<tr>
<td class="fullview-links" align="left" valign="center">
<a target="_blank" class="tab-link" href="https://finance.yahoo.com/quote/EXEL">open in yahoo</a> | <a target="_blank" class="tab-link" href="https://www.reuters.com/companies/EXEL.OQ">open in reuters</a> | <a target="_blank" class="tab-link" href="https://www.marketwatch.com/investing/stock/exel">open in marketwatch</a> | <a target="_blank" class="tab-link" href="https://www.google.com/finance/quote/EXEL:NASDAQ">open in google</a></td>
</tr>
</table>
</div></div>
            <div class="footer" style="margin-top: 20px">
                <div class="footer_links">
                    <a class="tab-link" href="/affiliate.ashx">affiliate</a>
                    <span class="footer_dot"> â€¢ </span>
                    <a class="tab-link" href="/advertise.ashx">advertise</a>
                    <span class="footer_dot"> â€¢ </span>
                    <a class="tab-link" href="/contact.ashx">contact</a>
                    <span class="footer_dot"> â€¢ </span>
                    <a class="tab-link" href="/privacy.ashx">privacy</a>
                    <span class="footer_dot"> â€¢ </span>
                    <a class="tab-link" href="/help/screener.ashx">help</a><br><a class="tab-link" href="/do_not_sell.ashx">Do not sell my personal information</a>
                </div>
                <span class="copyright">Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.</span>
                <br>
                Copyright Â© 2007-2021 FINVIZ.com. All Rights Reserved.</span>
            </div><script type="text/javascript">SearchFocus();</script>
            <script type="text/javascript" src="/js/libs/d3.js"></script>
            <script type="text/javascript" src="/assets/dist/quote.5801d53c.js"></script>
        <script>
            function FinvizReady(fn) {
              if (document.readyState != 'loading'){
                fn();
              } else {
                document.addEventListener('DOMContentLoaded', fn);
              }
            }

            (typeof StocktwitsInit === 'function' && FinvizReady(StocktwitsInit));
            (typeof SetSearchExt === 'function' && SetSearchExt('&ty=c&ta=1&p=d'));
        </script>
            <script async src="https://www.googletagmanager.com/gtag/js?id=UA-3261808-1"></script>
            <script>
              window.dataLayer = window.dataLayer || [];
              function gtag(){dataLayer.push(arguments);}
              gtag('js', new Date());

              gtag('set', {'dimension1': 'NotLoggedIn'});
              gtag('set', {'dimension3': window.devicePixelRatio || 'unknown'});

              gtag('config', 'UA-3261808-1', { sample_rate: 10, send_page_view: false });
              

              gtag('event', 'page_view', { page_location: location.href, page_path: location.pathname, page_title: document.title });
            </script>
        <script type="text/javascript">
_qoptions={qacct:"p-c2W8esUZ6Q8oA"};
</script>
<script type="text/javascript" src="https://secure.quantserve.com/quant.js"></script>
<noscript>
<img src="https://pixel.quantserve.com/pixel/p-c2W8esUZ6Q8oA.gif" style="display: none;" border="0" height="1" width="1" alt="Quantcast"/>
</noscript>
<div id="modal-elite-ad" class="modal-elite-ad">
                            <div id="modal-elite-ad_content" class="modal-elite-ad_content">
			                    <button id="modal-elite-ad-close" type="button" class="modal-elite-ad_close">Ã—</button>

                                <!--<div id="modal-elite-ad-content-0" style="display: none">
			                        <h2>Ever heard of Finviz*Elite?</h2>
                                    <p>
                                        Our premium service offers you real-time quotes, advanced visualizations, technical studies, and much more.<br>
                                        Become Elite and make informed financial decisions.
                                    </p>
                                    <a href="/elite.ashx?utm_source=finviz&utm_medium=banner&utm_campaign=modal-0" id="modal-elite-ad-btn-0" class="" target="_blank">Find out more</a>
                                </div>-->

                                <div id="modal-elite-ad-content-1" style="display: block">
			                        <h2>Upgrade your FINVIZ experience</h2>
                                    <p>
                                        Join thousands of traders who make more informed decisions with&nbsp;our&nbsp;premium features.
                                        Real-time quotes, advanced&nbsp;visualizations, backtesting, and much more.
                                    </p>
                                    <a href="/elite.ashx?utm_source=finviz&utm_medium=banner&utm_campaign=modal-1" id="modal-elite-ad-btn-1" class="modal-elite_button" target="_blank">Learn more about FINVIZ*Elite</a>
                                </div>
                            </div>
                         </div><script src="/js/pv.js?rev=282" async></script><script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6616fe7d5ef32de7","token":"e53f08f6c9e04bfd9760701085ec93b4","version":"2021.5.2","si":10}'></script>
</body>
</html>
